Trading Analysis Report: CARR¶

Generated: 2026-10-02 10:32:38

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 55.22 Price As Of: 2026-10-01

CARR (Carrier Global Corporation, NYQ): Technical Report¶

All price and indicator values below come from the verified snapshot or from tool output with explicit dates. Where the indicator tool and the snapshot overlap (close, 50/200 SMA, RSI, MACD histogram, ATR), they agree. I found no discrepancies.

1. Indicators chosen and why¶

I used 8 indicators that cover different jobs and don't duplicate each other.

Role	Indicator	Reason
Medium trend	close_50_sma	Dynamic resistance and medium-term direction
Long trend	close_200_sma	Strategic regime line
Multi-timeframe trend	supertrend	Weekly, monthly and daily trend state, with trailing-stop levels
Momentum turn	macdh	Early read on whether downside momentum is fading
Oversold/overbought	rsi	The stock fell sharply in September, so this shows how stretched it got
Volatility/risk	atr	Stop distance and position sizing
Volume confirmation	obv	Checks whether the bounce has volume support
Stretch	z_score	Mean-reversion gauge on three timeframes

2. Price context¶

Peak and decline: CARR's highest close in the pulled window (April to October 2026) was 75.73 on 2026-06-25. It has fallen to 55.22, about 27% lower on a closing basis.
Pullback after the peak:
A gap-down on 2026-07-28 took the close from 69.33 to 63.16 on 16.4M shares.
The next day it closed at 59.92 on 16.6M shares.
The tools don't say what caused these moves, so I won't name a catalyst.
A partial rebound to 65.69 on 2026-08-04 failed.
September slide:
The stock made a lower high and lower low through August and September.
The close reached 57.25 on 09-01.
It fell to 54.26 on 09-16 and 53.88 on 09-18.
The 09-18 intraday low of 52.96 is the lowest low in the window.
Volume capitulation: 09-18 had 21.4M shares, the heaviest volume in the window. 09-15 had 13.3M. The heavy volume on those down days looks like forced or capitulative selling, but the tools don't say why.
Current base: Since 09-18 the stock has held a 53.88–56.37 closing range:
Closes were 54.62, 55.26, 55.10, 54.87, 56.37, 55.87, 55.38, 54.86 and 55.22.
Lows since 09-18 have been above 52.96.
The most recent low is 54.00 on 10-01, which is the lowest in the post-09-18 range.

3. Trend: bearish on every horizon¶

Moving averages:
Price (55.22) is below the 50 SMA (59.77) and the 200 SMA (61.32).
The 10 EMA is 55.43, so price sits just under the shortest-term average.
50/200 cross:
The 50 SMA fell below the 200 SMA on 2026-09-24, from 60.9995 versus 61.25.
That is a death-cross configuration.
The 50 SMA is still falling, from 65.53 on 09-01 to 59.77.
The 200 SMA is nearly flat, rising from 60.96 to 61.32.
Cross signals lag, and this one came after a ~27% decline.
SuperTrend (higher tier wins):

Timeframe	Direction	Stop	Close vs stop
Weekly (primary)	DOWN	68.06	-18.86%
Monthly	DOWN	75.98	-27.32%
Daily	DOWN	59.29	-6.86%

There is no timeframe conflict.
The weekly and monthly stops are far away, so a trend flip on those timeframes would need a very large rally.
The daily stop at 59.29 is the nearest practical trend-change level. It is also close to the 50 SMA (59.77) and the Bollinger upper band (59.63), so that area is a resistance cluster at roughly 59.3–59.8.

4. Momentum: oversold, now stabilizing¶

RSI:
RSI is 39.92 now.
It was 26.996 on 09-01 and 27.14 on 09-18, both below 30.
Since 09-18 it has recovered into the high 30s and low 40s, with a peak of 43.77 on 09-25.
It is still below 50 and has not recovered into neutral territory.
Possible divergence: The 09-18 price low (53.88) was below the 09-01 price low (57.25), while the RSI low (27.14) was about equal to or marginally above the earlier one (27.00). That is a very mild bullish divergence at best. I would not treat it as a signal.
MACD:
MACD is -1.35, the signal line is -1.61, and the histogram is +0.25.
The histogram turned positive on 09-23 and has stayed positive.
The MACD line is above its signal line but still well below zero.
This means downside momentum has eased. It is not a confirmed trend reversal.
The histogram has plateaued (0.27 on 09-29, 0.24 on 09-30, 0.25 on 10-01), so the improvement has stalled.

5. Volatility and risk¶

ATR:
ATR is 1.56, about 2.8% of price.
It is down from a September peak of 1.90 on 09-17/09-18.
Volatility is easing after the capitulation.
Bollinger Bands:
The middle band is 56.14, the upper band is 59.63 and the lower band is 52.65.
Price is in the lower half of the band range, about 0.9 below the middle band.
It is 2.6 above the lower band.
It is not at a band extreme.
Stop sizing (illustrative):
2x ATR (about 3.11) from the current price implies a stop near 52.1.
That is just under the 52.96 swing low and the 52.65 lower band.
A close below ~52.65–52.96 would invalidate the basing idea and put CARR at new lows for the window.

6. Volume: not confirming the bounce¶

Bounce has no volume support: OBV fell from -27.75M on 09-04 to -79.79M on 10-01.
It dropped to -80.54M on 09-18.
It then reached -87.22M on 09-30, a lower low than on 09-18, even though price on 09-30 (54.86) was above the 09-18 close (53.88).
So OBV did not confirm the post-09-18 price stabilization.
OBV improved to -79.79M on 10-01 with the +0.66% close, but it is still negative and sloping down over the window.
Reading: Distribution has dominated September. Until OBV makes a higher low and turns up, the bounce is lower-quality.

7. Stretch¶

Z-score:
Weekly is -1.47, monthly is -1.08 and daily is -0.53.
None reaches the |z| ≥ 2 threshold.
The weekly reading is below the mean and approaching stretched territory.
There is no extreme mean-reversion signal.
Fading the downtrend on stretch alone isn't supported, because the daily reading is near fair value.
I did not include TD-9, so I have no sequential exhaustion reading.

8. Synthesis for the trader¶

Bias: the trend is bearish. Short-term stabilization is in progress but unconfirmed.

Bearish evidence: - All three SuperTrend tiers are down. - Price is below the 50 and 200 SMAs. - The 50/200 cross turned bearish on 09-24. - OBV made a lower low on 09-30. - RSI is still below 50.

Stabilizing evidence: - The stock has held above its 09-18 low for 8 sessions. - RSI recovered from below 30. - The MACD histogram has been positive since 09-23. - ATR is declining. - Weekly z-score is -1.47.

Levels (from verified data):

Level	Meaning
52.65–52.96	Lower Bollinger band and 09-18 intraday low; breakdown line
53.88	09-18 close
54.00	10-01 intraday low; first support
55.43	10 EMA
56.14	Bollinger middle; near-term pivot
56.37	09-25 close; top of the recent closing range
59.29–59.77	Daily SuperTrend stop, upper Bollinger band and 50 SMA
61.32	200 SMA
68.06	Weekly SuperTrend stop

Scenarios: - Base case (range or grind): CARR trades between about 54 and 56.4 until a catalyst arrives. Resistance sits around 56.1–56.4. - Bullish confirmation: - A close above ~56.4–56.5 on rising volume, with OBV turning up and RSI above 50, would raise the odds of a move toward the ~59.3–59.8 cluster. - That cluster is a resistance zone, not a trend change. - A weekly trend flip would need a much larger move (the weekly stop is 68.06). - Bearish continuation: A close below about 52.65–52.96, especially with rising volume, would end the basing attempt. That would resume the downtrend and put the stock at new lows for the window.

Risk management: ATR-based stops of about 2x ATR (~3.1) fit current volatility. Rallies into the 50 SMA and daily SuperTrend line are the logical places to reassess.

Limitations: - The data window runs from 2026-04-01 to 2026-10-01. - The tools provide no fundamental or news data, so the causes of the July and September high-volume drops are unverified. - TD-9, ADX and other indicators were not pulled. - A decision on whether to trade is left to the next agent.

Summary table¶

Item	Reading	Interpretation
Close (2026-10-01)	55.22	Verified; O 54.82, H 55.24, L 54.00, volume 7.43M
10 EMA	55.43	Price slightly below the short-term average
50 SMA	59.77 (falling)	Overhead resistance
200 SMA	61.32 (nearly flat)	Long-term resistance; price below it
50/200 relationship	50 SMA below 200 SMA since 2026-09-24	Death-cross configuration; lagging
SuperTrend weekly / monthly / daily	DOWN / DOWN / DOWN	Stops at 68.06 / 75.98 / 59.29; trend is bearish on all tiers
RSI	39.92	Recovering from ~27 (09-01, 09-18); still below 50
MACD / signal / histogram	-1.35 / -1.61 / +0.25	Downside momentum easing; below zero and plateauing
Bollinger (lower / mid / upper)	52.65 / 56.14 / 59.63	Price in lower half, not at an extreme
ATR	1.56 (~2.8% of price)	Volatility down from 1.90 peak in mid-September
OBV	-79.79M (low -87.22M on 09-30)	Does not confirm the bounce; distribution bias
Z-score weekly / monthly / daily	-1.47 / -1.08 / -0.53	Below mean, not stretched (
Key support	54.00, then 52.65–52.96	Breakdown line near 52.65–52.96
Key resistance	56.14–56.37, then 59.29–59.77	Pivot, then resistance cluster
Overall	Bearish trend, tentative short-term stabilization	Wait for volume and OBV confirmation, a close above ~56.4, or a break below ~52.65

Sentiment Analyst¶

Overall Sentiment: Mixed (Score: 4.7/10) Confidence: Low

Scope and data limits. Only one of three sources returned usable data. Yahoo Finance news was unavailable for 2026-09-24 to 2026-10-01 (the feed only serves recent items, so this is NOT evidence of no news for CARR). Reddit was disabled by config. StockTwits returned just 6 messages. Confidence is therefore low, and everything below rests on a thin retail sample.

1. Source-by-source breakdown

News (Yahoo Finance): No data. No institutional framing, earnings commentary, analyst actions or corporate events can be cited. I can't confirm or deny any catalyst from this source.

StockTwits (6 messages, 2026-09-25 to 2026-09-30): Labeled split is Bullish 2 (33%), Bearish 0 (0%), Unlabeled 4. The 0 bearish tags look more bullish than the content is. Two of the four unlabeled posts are clearly bearish in tone, so the tags understate the bearish side. - Bullish-tagged: @akinlxl (09-28) says CARR "should be much higher — quality products and easy to service". @Hihosilveraway11 (09-25) says "oversold". - Unlabeled but bullish-leaning: @stockpicker63 (09-27) calls it a "developing bullish reversal rather than an already-confirmed breakout". The post cites improving short-term price structure, increased volume and strong order/data-center fundamentals. It also says CARR remains below its 50- and 20-day averages (the text is truncated). - Unlabeled but bearish: @ItsCarRamRod (09-28) argues the MACD shows CARR is "way overbought" and expects new 52-week lows under $50. The same user on 09-30 says CARR falls about 2x as much as the market on down days and still falls on up days. @peloswing (09-30) reports over $1.6M of put flow on the $52 puts expiring 10/30. - Reading the posts, my judgment is roughly 3 bullish-leaning and 3 bearish-leaning. That is about an even split, and it is small enough that one or two posts could flip it.

2. Cross-source divergences and alignments No cross-source comparison is possible because news and Reddit are missing. Within StockTwits there is a split between the user-tagged labels (all bullish) and the unlabeled content, which includes bearish positioning and an options-flow signal. Both "oversold" (09-25) and "way overbought" (09-28) appear, so retail is not agreed on the short-term technical state. Both claims are unverified opinion.

3. Dominant narrative themes - Technical debate: oversold vs. overbought, a possible bullish reversal vs. a break to new lows. The price is described as below its 20- and 50-day averages and near 52-week lows. The $50 level is cited as a downside marker and $52 as a put strike. These are retail claims, not verified price data. - Relative weakness: one user says CARR underperforms in both up and down markets. - Fundamental bull case: quality products, serviceability, orders and data-center exposure. This is a single-user or two-user theme. - Options positioning: a large put print for 10/30 expiry that points to hedging or bearish speculation. The flow is reported by a retail user and not independently verified, and a single print could be a hedge or part of a spread.

4. Catalysts and risks surfaced - Catalysts (from the posts): data-center and order momentum, a possible technical reversal on rising volume. - Risks: a break below the 52-week low (under $50), heavy put flow into 10/30, persistent underperformance, and price below key short-term averages. - Not covered by the data: the next earnings date, analyst rating changes, guidance, and macro or sector news. I can't comment on any of these.

5. Summary table

Signal	Direction	Source	Evidence
Tagged retail ratio	Bullish	StockTwits	2 bullish, 0 bearish, 4 unlabeled (n=6)
Content-level read	Mixed	StockTwits	About 3 bullish-leaning vs. 3 bearish-leaning posts
Put flow	Bearish	StockTwits	Over $1.6M in $52 puts expiring 10/30 (unverified)
Technical debate	Mixed	StockTwits	"Oversold" (09-25) vs. "way overbought", new lows under $50 (09-28)
Reversal / orders / data-center thesis	Mildly bullish	StockTwits	@stockpicker63 (09-27); price still below the 20/50-day averages
Relative weakness	Bearish	StockTwits	"Goes down 2x as much" (09-30)
Institutional news	No data	Yahoo Finance	Feed unavailable, not evidence of silence
Reddit	No data	Reddit	Disabled by config

Bottom line: Sentiment is Mixed, with a score slightly below neutral (4.7) because of the put flow and the bearish technical calls. The sample is only 6 messages, so the signal is weak and the trader should weigh it against fundamentals, technicals and any news obtained elsewhere. Past sentiment is not predictive.

News Analyst¶

CARR (Carrier Global Corporation): news and macro report for the week of 2026-09-24 to 2026-10-01¶

1. Data coverage¶

Most of what I tried returned nothing. The report is thin, and I have not filled the gaps with guesses.

Source	Status
CARR company news (two windows: 9/24–10/1 and 9/1–10/1)	Unavailable. The vendor said it only serves recent items. It said this is not evidence that CARR had no news.
FRED macro series (fed funds, 10-year Treasury, CPI, unemployment, yield curve)	Unavailable. The FRED API key is not configured. I have no numbers for any of these series.
Prediction markets (Fed cut, recession 2026)	Withheld for 2026-10-01, to avoid look-ahead bias.
Global news feed	Available, but mostly mining and IT-services headlines. Only a few items bear on the macro picture.

2. CARR-specific findings¶

I found no CARR-specific news, catalysts, analyst actions or earnings items for this week. I cannot say whether there were any.

3. Macro and market backdrop¶

These points come only from headlines. I did not read the article text, so the details are unverified.

Equities rebounded on 10/1. A Yahoo Finance headline says the Dow, S&P 500 and Nasdaq "stage comeback as Treasury yields fall, chip stocks gain." That implies the market was weaker beforehand, and that yields fell on the day. I have no yield levels.
Fed officials are hawkish. A Yahoo Finance headline reads "Chorus of Fed officials warn inflation is still too high, signaling more work to do on interest rates." This points to a restrictive bias. It conflicts with the day's fall in yields, so the two are worth watching together.
PCE data came out. A silver-price article on 10/1 mentions "the latest PCE report." I don't have the figure or the market's reaction.
A cautionary voice on valuations. Gundlach is quoted warning that the stock market is "a hollow tree that could be about to snap." This is one opinion. It does suggest narrow market leadership and a fragile rally.
Strong IT-services and AI-adjacent earnings. Accenture jumped roughly 20–23% on record bookings and a strong 2027 outlook. IBM, Infosys, EPAM, DXC and others also rose. This is a sign of healthy enterprise demand, mostly in tech and not in building products.
Commodities. The feed carried a Barchart September commodity performance review, plus silver and gold items. It gave no price detail.

4. Implications for CARR¶

These are inferences from the limited evidence, not findings.

CARR is a building products and HVAC company. It is sensitive to interest rates through housing, commercial construction and financing costs.
Falling yields and a market rebound would help the stock.
Hawkish Fed commentary would work against it.
Strong data-center and AI-related demand headlines could matter for HVAC and cooling. Nothing in this feed ties them to CARR.
A fragile, narrow market raises the risk of a pullback in cyclicals.

5. What is still needed¶

CARR price action, technicals and any recent company news, from other tools.
Actual levels for the fed funds rate, 10-year yield, CPI, PCE, unemployment and the yield curve.
Market-implied rate-cut and recession odds.
Whether CARR has an earnings date or an investor event coming up.

6. Summary table¶

Area	Evidence	Reliability	Possible read-through for CARR
CARR news	None retrievable	No data	Unknown
Equity market, 10/1	Rebound as yields fell, per headline	Headline only	Mildly supportive for a rate-sensitive cyclical
Fed tone	Officials warn inflation is still too high	Headline only	Restrictive bias is a headwind for housing and construction
PCE	Released, no figures available	Not usable	Unknown
Market risk	Gundlach warns of a fragile market	One opinion	Pullback risk for cyclicals
IT-services earnings	Accenture +20–23%, IBM +5%	Headlines	Healthy enterprise demand; indirect link to CARR at most
Commodities	Metals news and September review	Little detail	Little direct link
FRED macro series	API key missing	No data	Cannot be assessed
Prediction markets	Withheld to avoid look-ahead	No data	Cannot be assessed

Fundamentals Analyst¶

CARR (Carrier Global Corporation): Fundamental Report as of 2026-10-01¶

Scope and data limits - The get_fundamentals profile call was withheld for this date. The vendor only serves present-day values, so I have no market cap, P/E, EV/EBITDA, dividend yield or 52-week range. I have not estimated valuation multiples or quoted a current share price. - Everything below comes from the quarterly income statement, balance sheet, cash flow and insider tools. - The latest reported quarter is Q2 FY2026 (period ended 2026-06-30). Q3 ended 2026-09-30 and has almost certainly not been reported yet. - TTM figures below are my own sums of the last four reported quarters (Q3'25 to Q2'26).

1. Income statement¶

Quarter	Revenue	Gross profit (margin)	Operating income (margin)	EBITDA	Net income	Diluted EPS
Q2'25	$6,113M	$1,769M (28.9%)	$795M (13.0%)	$1,244M	$591M	$0.68
Q3'25	$5,579M	$1,449M (26.0%)	$495M (8.9%)	$874M	$428M	$0.50
Q4'25	$4,837M	$961M (19.9%)	$54M (1.1%)	$449M	$53M	$0.06
Q1'26	$5,341M	$1,244M (23.3%)	$240M (4.5%)	$596M	$238M	$0.28
Q2'26	$6,351M	$1,728M (27.2%)	$770M (12.1%)	$1,161M	$501M	$0.60

TTM (Q3'25 to Q2'26) - Revenue is about $22.1B. - EBITDA is about $3.08B. - Net income is about $1.22B. - Diluted EPS is about $1.44.

Q2'26 versus Q2'25 - Revenue rose 3.9%. - Gross margin fell about 170 bp, from 28.9% to 27.2%. - Operating margin fell about 90 bp, from 13.0% to 12.1%. - Operating income fell 3.1%. - EBITDA fell 6.7%. - Diluted EPS fell 11.8% (0.68 to 0.60). The tax rate rose to about 25% from about 20%, and minority interest took $40M. A lower share count (836.5M versus 866.3M diluted, down 3.4%) partly offset this.

Sequential trend - The business is clearly seasonal, with Q2 the strongest quarter and Q4 and Q1 the weakest. - The Q4'25 trough was severe: gross margin 19.9% and operating margin 1.1%. - Q2'26 recovered strongly from Q1. - Revenue growth is low-single-digit. Margins are below the prior-year level, so growth is not yet translating into profit.

Other items - Interest expense has risen from $115M to $126M per quarter. Net interest expense was $105M in Q2'26. - Equity-method earnings were $58M in Q2'26 against $78M a year ago. - The Q1'26 tax provision of -$96M and the Q4'25 provision of -$32M flatter pretax-to-net conversion. The tax line is noisy, so compare operating income and EBITDA rather than EPS. - Discontinued operations were small: -$1M in Q1'26 and $0 in Q2'26, after +$25M in Q4'25. - SG&A was $810M in Q2'26, about 12.8% of revenue. R&D was $148M, about 2.3% of revenue.

2. Balance sheet (2026-06-30)¶

Total assets: $37.4B.
Total liabilities: $23.9B, up from $23.1B at year-end.
Equity: common equity $13.1B, down from $14.7B a year ago. Total equity including minority interest is $13.5B.
Goodwill and intangibles: $21.0B, about 56% of assets. Tangible book value is -$7.9B.
Debt: total debt is $12.4B and net debt is $10.6B. Cash is $1.34B.
Long-term debt is $10.3B.
Current debt is $1.64B, up sharply from $468M at year-end. It includes $685M of commercial paper and $953M of other current borrowings.
Leverage: net debt to TTM EBITDA is about 3.4x, and total debt to TTM EBITDA is about 4.0x. TTM EBIT over interest is about 3.8x. EBITDA is depressed by the weak Q4 and Q1 quarters.
Liquidity: the current ratio is about 1.02, with current assets of $9.41B against current liabilities of $9.23B.
Working capital fell from $1.42B at year-end to $183M.
Cash has declined from $1.80B in June 2025.
Working capital items: receivables are $3.25B (up from $2.64B at year-end, seasonal). Inventory is $2.76B (up from $2.48B). Payables are $3.22B.
Assets held for sale: these have grown to $815M, from $592M at year-end and $621M in March. This suggests an active divestiture.
Share count: ordinary shares outstanding were 825.0M, versus 850.8M a year earlier, a decline of about 3.0%.
Treasury stock rose from $5.5B to $7.55B.
The "Share Issued" figure for June 2026 (825M) looks like a vendor data inconsistency against the prior 951M.

3. Cash flow¶

Quarter	Operating CF	Capex	Free cash flow	Buybacks	Dividends
Q2'25	$649M	$81M	$568M	$340M	$192M
Q3'25	$341M	$117M	$224M	$785M	$193M
Q4'25	$1,040M	$131M	$909M	$479M	$189M
Q1'26	$79M	$94M	-$15M	$306M	$201M
Q2'26	$927M	$117M	$810M	$439M	$199M

TTM - Operating cash flow is about $2.39B. - Capex is about $459M. - Free cash flow is about $1.93B, which is about 88% of TTM net income. - Buybacks are about $2.01B and dividends about $782M, a total of about $2.79B returned. - Shareholder returns therefore exceeded FCF by about $0.86B. The gap was funded by cash drawdown and by commercial paper, which added $371M in Q1'26 and $444M in Q3'25.

Other cash flow points - D&A is steady at about $315M per quarter. - Stock-based compensation is small, at $12M to $21M per quarter. - Q2'26 working capital was a -$59M drag. Payables were a +$280M source, offset by receivables of -$142M and inventory of -$197M. - Cash flow is heavily weighted to Q2 and Q4. Q1 is typically near zero or negative. - Investing outflows are mostly capex plus small acquisitions ($31M in Q2'26).

4. Insider activity¶

Material transactions - Maximilian Viessmann (Director, indirect holding): - Sold 12.09M shares at $62.01 on 2026-05-20, about $750M. - Sold 4.27M shares at $70.30 on 2025-06-05, about $300M. - This is about 16.4M shares and about $1.05B sold in 12 months. He appears to be exiting the stake received in the Viessmann Climate Solutions deal. The sales are large and repeated, and the price was lower in the second sale. - David Gitlin (CEO): open-market purchase of 19,300 shares at $52.62 on 2025-11-25, about $1.02M. This is a discretionary buy at a lower price than the director sales. - Annual stock awards (2026-01-30, price $0): Gitlin 90,872 shares, CFO Goris 40,750, Villeneuve 15,194, Agrawal 5,705, Pandya 5,705, Campbell 1,958. These are routine grants, and the 2026 sizes are smaller than the 2025 grants. - Smaller entries with no transaction type listed (Dryden, Pandya, Gierges, Heim): these are probably tax withholding or similar administrative transactions and carry no clear signal. - Earlier sales: Kyle Crockett (Feb 2025, about $1.2M at $65.18) and Kevin O'Connor (Nov 2024, about $12.3M at $73.46).

Read-through: the only open-market purchase in the window is the CEO's roughly $1M buy. The director's large sales are the dominant supply overhang. They are probably a portfolio decision, not an operating signal. Insider prices ($73 in Nov 2024, $65 in Feb 2025, $70 in June 2025, $52.62 in Nov 2025, $62.01 in May 2026) show that the stock has been range-bound to lower.

5. Takeaways for traders¶

Positives - Q2'26 revenue grew about 4% year over year, with a strong sequential recovery from Q1. - TTM free cash flow is about $1.9B, and Q2'26 FCF of $810M was strong. - The share count is falling about 3% a year through buybacks, with a steady dividend of about $0.24 per share per quarter (about $199M). - The CEO bought shares in the open market. - The $815M of held-for-sale assets points to portfolio pruning that could cut debt.

Risks - Margins are compressing. Gross margin is down about 170 bp year over year and operating income and EBITDA are lower. EPS fell about 12%. - Leverage is elevated, at about 3.4x net debt to EBITDA, and short-term debt has jumped to $1.64B. - Working capital has nearly vanished ($183M) and cash is falling. - Buybacks plus dividends exceed FCF, so the current return pace depends on commercial paper or the divestiture proceeds. - Tangible book value is deeply negative, with 56% of assets in goodwill and intangibles. - A director has sold about $1.05B of stock in 12 months, which may weigh on the share price. - Results are highly seasonal, so Q3 and Q4 comparisons need care.

Things to watch - The Q3'26 report: whether year-over-year margin compression continues, and what the Q3 FCF is. Q3'25 was only $224M. - Whether the held-for-sale assets close and how the proceeds are used (debt paydown or buybacks). - Any further Form 4 filings from Viessmann. - Management's FY2026 guidance, which is not in these tools and needs another source.

Summary table¶

Category	Key data point	Implication
Data limits	Profile, valuation and price data withheld	No valuation view from these tools
Q2'26 revenue	$6.35B, +3.9% YoY	Modest growth
Q2'26 margins	Gross 27.2% (-170 bp), operating 12.1% (-90 bp)	Margin compression
Q2'26 EPS	$0.60 vs $0.68 (-11.8%)	Earnings decline despite lower share count
TTM revenue / EBITDA / EPS	~$22.1B / ~$3.08B / ~$1.44	Baseline for valuation
Seasonality	Q4'25 operating margin 1.1%, Q1'26 4.5%, Q2'26 12.1%	Q3 and Q4 comparisons need care
Free cash flow	TTM ~$1.93B (Q2'26 $810M, Q1'26 -$15M)	Solid but lumpy; ~88% of net income
Shareholder returns	TTM buybacks ~$2.0B plus dividends ~$0.78B	Exceeds FCF by ~$0.86B
Share count	825M, -3.0% YoY	Supports EPS
Net debt / EBITDA	$10.6B; ~3.4x TTM	Elevated leverage
Short-term debt	$1.64B (vs $0.47B at YE'25)	Refinancing and CP reliance
Liquidity	Current ratio ~1.02; working capital $183M	Thin cushion
Intangibles	Goodwill and intangibles $21.0B; tangible BV -$7.9B	Impairment and balance sheet risk
Held for sale	$815M, rising	Possible divestiture and deleveraging
Insider selling	Viessmann: 12.09M shares at $62.01 (~$750M, May 2026); 4.27M at $70.30 (~$300M, Jun 2025)	Supply overhang
Insider buying	CEO Gitlin: 19,300 shares at $52.62 (~$1.0M, Nov 2025)	Modest confidence signal
Watch list	Q3'26 results, divestiture closing, further Form 4s, guidance	Near-term catalysts

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for CARR (Carrier Global, $55.22)

I'll open with the bull thesis and put the weak spots on the table early, so the bear and I are debating the real issues.

My thesis: CARR is a cash-generative HVAC franchise whose stock has been marked down about 27% from its June peak (75.73) into a heavy-volume capitulation. At roughly $55, the market is pricing the trough quarters as if they were permanent. I see a tactical entry with defined risk now and a fundamental re-rating if the Q3 and Q4 margin trend improves.

1. The business is cash-generative, and the market is ignoring it¶

TTM free cash flow is about $1.93B. Against a market cap of roughly $45.6B (my own math: 825M shares × $55.22), that is about a 4.2% FCF yield. Add the roughly $0.96 annual dividend and the total shareholder yield is about 6%.
Q2'26 FCF was $810M, up from $568M a year earlier. Revenue grew 3.9% to $6.35B, and operating margin recovered from 4.5% in Q1 to 12.1%.
The share count is down about 3% year over year (825M vs. 850.8M). That cushions EPS even when margins are soft.
The CEO put his own money in. David Gitlin bought about $1M of stock at $52.62 in November 2025. The stock is only about 5% above that price today.

2. The bear's trailing multiple is misleading¶

Someone will point out that $55.22 over TTM EPS of about $1.44 is roughly 38x. That figure is distorted by the seasonal trough. Q4'25 EPS was $0.06 and Q1'26 was $0.28. This business earns most of its profit in Q2 and Q3. FCF and EBITDA (about 18x EV/TTM EBITDA on my math, with the same trough caveat) are the fairer lenses, and neither looks stretched for a franchise with a service and aftermarket base.

3. The technical setup is a washout with defined risk¶

I'm not claiming the trend has turned, because it hasn't. But:

09-18 was capitulation. Volume was 21.4M shares, the heaviest in the window, and RSI hit 27.1.
The stock has held above that low for 8 sessions. It has traded in a 53.88–56.37 closing range, and ATR is falling from 1.90 to 1.56.
The MACD histogram has been positive since 09-23. Downside momentum is easing.
Risk is defined. The invalidation line is 52.65–52.96, about 4–5% below the current price. Targets are the 59.3–59.8 resistance cluster (about +8%) and the 200 SMA at 61.32 (about +11%). That is roughly 1.6:1 to 2.3:1 reward-to-risk.
Macro helped on 10/1. Equities rebounded as yields fell, per headlines only. Falling yields help a rate-sensitive cyclical like CARR.

4. Anticipating the bear¶

"Margins are compressing." That is true. Q2 gross margin fell 170 bp, operating income fell 3.1%, and EBITDA fell 6.7%. But part of the 11.8% EPS decline is below the operating line. The tax rate rose to about 25% from about 20%, and minority interest took $40M. Operating profit on 3.9% revenue growth is roughly flat, not collapsing. The Q3 report is the test. The market has already marked down the stock about 27% for this.

"Buybacks and dividends exceed FCF, funded by commercial paper." This is the bear's best fundamental point. TTM returns were about $2.79B against $1.93B of FCF, and short-term debt rose to $1.64B. But buybacks are discretionary. Management can slow them, and the $815M of assets held for sale can fund deleveraging. Net debt/EBITDA of about 3.4x is flattered upward by trough quarters in the TTM base. Interest coverage of about 3.8x is adequate, not alarming.

"A director sold about $1.05B of stock." Maximilian Viessmann sold 12.09M shares at $62.01 in May and 4.27M at $70.30 in June 2025. That is a real supply overhang, but it looks like a portfolio exit from the Viessmann deal, not an operating signal. I can't confirm how much he still holds, so I'd watch the Form 4s.

"Death cross, all SuperTrend tiers down, OBV at a lower low." All true. The cross lagged a 27% decline, and the 200 SMA is flat, so the cross is not accelerating. OBV not confirming is why I'd want a close above about 56.4 on rising volume before adding. I'm not asking anyone to catch a falling knife without a stop.

"$1.6M of put flow at the $52 strike." It is a single, unverified retail report, and it could be a hedge or part of a spread. It also marks $52 as where traders see support, which lines up with my line in the sand.

Where I'm candid about the data¶

Company news, guidance, analyst actions and the next earnings date were unavailable. I can't tell you what drove the July 28 gap-down or the September selling.
The data-center and order-strength thesis comes only from retail posts and is unverified. I treat it as upside optionality, not a pillar.
Sentiment is a six-message sample, so I'm leaning on it very little.

What would change my mind¶

A close below about 52.65 on rising volume.
Q3 gross margin compressing again year over year.
Debt-funded buybacks continuing while FCF stays flat.

I'll let the bear take it from here. Which of these is the real problem: the margin trend, the balance sheet, or just a broken chart? Bull Analyst: # Bull Rebuttal for CARR ($55.22): You Found the Right Problems and Over-Weighted Two of Them

Most of your case is fair. I'll start with what I'm giving up, then say where I think the weight is wrong.

What I concede¶

Seasonality doesn't excuse the TTM numbers. TTM is a full cycle. My "trough distortion" argument fails for the P/E, and for the 3.4x leverage too, since that is also a full-year ratio.
The 6% shareholder yield double-counts. The real figures are a 4.2% FCF yield, of which the dividend is 1.7% and is covered about 2.5x. Cash returned was 6.1% of market cap, which exceeds FCF.
"Operating margin recovered from 4.5% to 12.1%" was a seasonal comparison. The like-for-like figure is 13.0% to 12.1%.
Operating income fell 3.1% on 3.9% sales growth. That is a negative incremental margin, not "flat."
I'm dropping the put flow and the "yields fell" macro read. Both are unverified headline-level material.
Held-for-sale proceeds refill the hole rather than delever.
Gap risk is real. A stop 4.7% away does not protect against a -13.6% two-day move.

1. The 38x and 36x multiples charge full non-cash D&A¶

D&A runs about $315M a quarter, roughly $1.26B a year, against $459M of capex. That is why TTM FCF of $1.93B is 158% of TTM net income of $1.22B. The fundamentals report says 88%, which doesn't reconcile with its own table.

P/E and EV/EBIT charge all of that D&A. Goodwill and intangibles are 56% of assets, so I'd infer a large share is acquisition amortization, though the tools don't split it. On cash measures the stock looks like:

About 24x price to FCF.
About 21x EV to (EBITDA minus capex).

That isn't cheap and I won't call it cheap. It is also not 36–38x. One caveat: Q4'25 produced $1.04B of operating cash flow on $53M of net income, so seasonal working-capital release is in the FCF. A full year should net most of it out, but I can't verify that from this data.

2. The buyback isn't the load-bearing wall¶

Net income fell 15.2% and diluted EPS fell 11.8%, so a 3.4% lower share count was worth about 3.4 points of EPS.

A self-funded buyback is FCF minus dividends, about $1.15B against $2.01B actually spent. That is roughly 57% of the current pace.
Moving to that pace would shrink the EPS cushion by about 1.3 points a year and require no new borrowing.
That answers your "contradiction." Yes, slowing buybacks removes some cushion, and the cushion is cheap to give up.
If the thesis were "EPS growth through repurchases," you'd be right. Mine is that margin and cash conversion are the thesis. The wall that carries load is gross margin.

On "capital destroyed," our data has no repurchase prices. The one Q4'25 price point is the CEO's $52.62 buy in November, and Q4'25 buybacks were $479M. Some Q2'26 repurchases were probably done at higher prices, but "mostly above $55" isn't established.

3. Q2: the damage sits in one line¶

Gross margin: 170 bp is about $110M of Q2 gross profit, roughly 14% of operating income. That is the whole debate.
Operating costs: gross profit minus operating income fell from $974M to $958M. Costs fell $16M on 3.9% higher revenue, so the cost line is behaving.
EBITDA and net income: $58M of the $83M EBITDA decline sits outside operating income, and equity income explains $20M of it. Of the roughly $90M net income decline, only about $25M is operating income. The rest is equity income, +$11M of interest, the tax rate moving from about 20% to 25%, and $40M of minority interest. Those are real costs, but not all of them are operating deterioration.

I can't diagnose the 170 bp from this data. Price, mix and input cost are all possible. Nor can I tell whether it is widening or narrowing, because we only have the Q2 year-over-year comparison.

4. Balance sheet: watch it, but it isn't a stress signal¶

Equity down 11% (from $14.7B to $13.1B) is the buyback in accounting form. Treasury stock rose $2.05B, more than the entire $1.6B equity decline.
Negative tangible book is a goodwill artifact. I agree the equity is a claim on earnings, and that is all an equity claim ever is.
Commercial paper is $685M of $12.4B debt, about 5.5%.
The $953M of other current borrowings I can't identify. A current portion of long-term debt would be a refinancing item rather than a liquidity warning, but that is unverified.
Interest coverage of about 3.8x is adequate.

The test for me is that current debt, which was $468M at year-end and $1.64B at June 30, stops rising.

5. The chart: some of your points hold, some don't¶

10/1 tape: CARR opened at 54.82, hit 54.00 and closed at 55.22, within two cents of the 55.24 high. It rejected the range low and closed at the high of the day.
OBV is mechanical. The 10/1 up day added the full 7.43M shares, from -87.22M to -79.79M, which is already above the 09-18 reading of -80.54M. I agree the real test is a higher low than -87.22M.
Volume comparison: 7.4M against the 21.4M capitulation day proves nothing, and the tools give no average volume.
Lower closes: you're right that closes faded from 56.37 to 54.86 before the bounce.
Targets are resistance, and I'd trim at 59.3–59.8.
Risk/reward: I'll take 1.3–1.6:1 to the first target, depending on whether the stop is the 52.1 ATR level or a 52.65 close. That is modest. The edge has to come from the second leg.

6. What I can't see¶

The 07-28/29 drop of -13.6% on 16–17M shares each day coincides with typical late-July Q2 reporting. That is an inference, because the tools name no catalyst. If it was the Q2 print, then the 170 bp compression and the 11.8% EPS decline are already priced.

If guidance changed, that is the unseen risk in my thesis. The drop from $75.73 to $55.22 removed about $17B of market cap, against a $25M quarterly decline in operating income. Either the market is pricing a trajectory I can't see, or it has over-extrapolated. I can't resolve that, so I would size for it.

On insiders, comparing the CEO's $1M cash buy to a director's $1.05B exit of a deal-acquired stake is not like for like. I concede the supply overhang and would watch Form 4s. A lack of insider buying in the weeks around quarter-end is weak evidence, since insider-trading blackout windows are standard practice, though that is general knowledge, not something in our data.

Where we actually agree¶

We've converged on the same rules:

Confirm: a close above about 56.4–56.5 on rising volume, with a higher OBV low.
Invalidate: a close below 52.65.
Fundamental test: Q3 gross margin at or above 26.0%.

The only disagreement is whether to hold a starter position before the print. My answer is about one-third size, sized so a repeat of the 14% gap is survivable. I'd add on the confirmation, exit on a close below 52.65, and trim at 59.3–59.8.

Your own change-my-mind list asks for Q3 gross margin at or above 26.0%, buybacks cut to FCF minus dividends, and a volume-confirmed close above 56.5. None of that is exotic for a business with $810M of quarterly FCF. If those three arrive, what is left of the bear thesis? Bull Analyst: # Bull Closing for CARR ($55.22): The Disagreement Is Now Narrow

You've conceded the 38x and 36x multiples, the 88% figure, the working-capital caveat and the volume comparison. I'll do the same where your arithmetic holds, then say where I think you still over-weight the risks.

What I concede¶

24x FCF isn't cheap. I called it "not cheap" last round and still do.
Repurchase prices were probably above today's. Your $78 ceiling is right, and with only ~1M shares a year of SBC issuance, the average was likely in the high $60s or $70s. The buyback has lost money on mark-to-market.
At the Q1–Q2 pace, Q3 borrowing is likely. Your $500–640M requirement against last year's $224M Q3 FCF is correct.
The $38M EBITDA residual is unexplained. I can't identify it.
"Already priced" is unproven. The stock's slide after 07-29 is consistent with continued fundamental repricing.
A starter position departs from "confirm first." I'd argue it's a staged rule, not a rule-free one, and I come back to that below.

1. The Q2 FCF jump was mostly a weak comp¶

We agree the swing is about $370M. Where does it sit? Using your inputs (D&A ~$315M, SBC ~$15M), operating cash flow versus net income plus D&A plus SBC was:

Q2'25: $649M against ~$921M, about -$270M.
Q2'26: $927M against ~$831M, about +$95M.

The cash flow table also shows only a -$59M working-capital drag in Q2'26. So most of the swing is a depressed Q2'25 normalizing, not Q2'26 being flattered. You've already conceded that TTM operating cash flow is about $150M below net income plus D&A plus SBC. Across a full cycle, cash conversion isn't inflated.

2. The stock de-rated while trailing FCF rose¶

You showed the P/E went from 50x to 38x. On the cash measure we both now accept:

At the $75.73 peak: TTM FCF through Q1'26 was ~$1.69B. At the current 825M shares, that is about 37x (my arithmetic).
Today: TTM FCF is $1.93B, about 24x.

Price fell 27% while trailing FCF rose about 14%. That is a real de-rating, not a collapse in cash generation. The seven weeks of further decline after 07-29 may mean the market wasn't done repricing. But it is equally consistent with supply: a 21.4M-share capitulation day, and a director who sold 12.09M shares in May with an unknown remaining stake. I can't separate the two readings, and neither can you.

3. The buyback is a sunk cost and a decelerating one¶

The overspend is concentrated. Quarterly surplus or deficit after dividends was -$754M (Q3'25), +$241M (Q4'25), -$522M (Q1'26) and +$172M (Q2'26). Two quarters account for the whole $0.86B gap.
The pace is falling. Buybacks went $785M, $479M, $306M, $439M. The last three quarters averaged $408M, about half the Q3'25 level.
Carrying cost is small. By your own math the overspend costs roughly 2% of net income, so it isn't a solvency story.
Self-funding means measuring over a year. Q3 is the seasonally weakest FCF quarter, and Q4'25 produced a $241M surplus. Current debt rising in Q3 and falling back in Q4 would be seasonal financing, not stress. I'd still want year-end debt lower than June's.
Cheaper stock retires more shares. A dollar spent at $55 retires about 27% more shares than at $70. The cost of past purchases is sunk. The forward question is the pace.

4. The waterfall is steeper above the operating line than below it¶

EBITDA fell $83M, but vendor EBITDA includes non-operating items, so the $58M gap to operating income can include things other than operating trouble. I can't prove that. The cleaner read is operating income, down $25M (-3.1%) on +3.9% revenue. That is a negative incremental margin, and I've conceded it. It is also a smaller problem than "EBITDA -6.7%" suggests. Opex fell $16M, so gross margin is the issue. You're right that I can't see why it fell 170 bp, and that is a gap in my thesis.

5. Sequencing: both sides rest on an unseen variable¶

You say my thesis rests on a line I can't see. Your -13.6% precedent rests on the same missing guidance data, and you've admitted you can't tell me the skew either.

On sizing:

A one-third position hit by another -13.6% gap loses about 4.5% of a full position. That is roughly what a full-size position loses at my stop.
The earlier gap came off a $69 stock at ~50x trailing EPS. Today's starting point is 24x FCF after a 27% drawdown. That doesn't guarantee a better reaction, but it isn't the same setup.

On the cost of waiting, you accept "a few points." Your neutral trigger needs a good print, buyback cuts and a price confirmation. By the time all three are visible, the stock is probably near the 200 SMA (61.32). At $62 the multiple is about 26.5x FCF, and you'd be paying a higher multiple for lower uncertainty. That is a reasonable trade, and I'd call it a preference rather than a refutation.

Where we land¶

My plan, unchanged but tighter:

Starter: one-third size at about $55.
Add: on a close above ~56.5 with rising volume and OBV making a higher low than -87.22M.
Exit: on a close below 52.65, with no averaging down.
Trim: at 59.3–59.8, since I agree that cluster is resistance.
Print rule: if Q3 gross margin comes in below 26.0%, or current debt keeps rising with buybacks unchanged, I cut the position rather than argue with the tape.

What remains of the bull case: cash flow is real over a full cycle, the dividend is covered 2.5x, and the stock has de-rated on a trailing-FCF basis. The cash-flow case is solid but not cheap. My edge is the entry price relative to the confirmation levels, not a mispricing, and I'd keep the size small for that reason. The unverified data-center and order-strength talk is optionality only.

Data caveats: guidance, company news, the earnings date, peer multiples, repurchase prices and average volume were unavailable. The Q2 OCF decomposition, the 37x peak FCF multiple and the 4.5% gap-loss figure are my arithmetic from the tables, assuming D&A of ~$315M, SBC of ~$15M and 825M shares at both dates. Bull Analyst: # Bull Rebuttal for CARR ($55.22): The Rules Need Fixing, but the Case for a Small Starter Survives

You've narrowed this to one question: own it into the print, or wait? I'll concede where you're right, fix my rules, and say what I still think you over-weight.

What I concede¶

My peak-multiple comparison was flattered. The 37x FCF at the $75.73 peak was inflated by a weak Q2'25 sitting in the TTM base, so "37x to 24x" overstates the de-rating. I'm dropping the de-rating framing and defending only the 24x.
My Q3 gross margin rule was badly written. As written, it fires on any decline from 26.0%. A repeat of Q2's -170 bp would put Q3 near 24.3% and trip it.
My debt rule fires on seasonality. Q3'25 also saw commercial paper added, so a Q3 rise isn't new information.
The starter has no technical support. The tape is bearish on every tier. My case for it is valuation plus cash flow, not the chart.
The Q3 overspend is likely. Your $500–640M requirement against about $224M of FCF is correct.

1. The FCF quality question favors me¶

You say FCF rose on a comp while earnings fell. The comp cuts both ways. A weak Q2'25 made last year's TTM FCF look low, and today's TTM is the cleaner figure. TTM operating cash flow of $2.39B is about 94% of net income plus D&A plus SBC (~$2.54B), which is below 100%, so the cash isn't flattered. That's why 24x is the number we both use. I'm not claiming a bargain, only that the cash base is real, the dividend is covered about 2.5x, and the price isn't paying for growth that has already failed.

2. Revised rules, with a self-serving warning¶

You'll say moving my rules after you caught them is convenient. I'll put the revision in a form you can check:

Gross margin ≥26.0%: thesis confirmed, add on price confirmation.
Between about 24.3% and 26.0%: compression is narrowing. No add, hold the starter, trim at 59.3–59.8.
At or below about 24.3%, i.e. -170 bp or worse: cut.
Buyback test: judged on management's stated pace and on year-end debt versus June's $1.64B current debt, not on the Q3 balance sheet.

The middle zone is a judgment call, and EPS is still falling there. In that zone I'm holding a small trade with a stop, not a re-rating thesis.

On "cut after the gap at the gapped price": yes, a stop can't protect against a gap. That is why the position is one-third size. The worst repeat of -13.6% costs about 4.5% of a full position, and that is the price of the option.

3. The buyback story is more seasonal than leveraged¶

You said the pace "re-accelerated" to $439M in Q2. But Q2 FCF after dividends was $611M, so that quarter's buyback was fully self-funded, with a $172M surplus. The two deficit quarters were Q3'25 (-$754M) and Q1'26 (-$522M), the seasonally weak ones. The pattern is buying in cash-rich quarters and borrowing in cash-poor ones.

If Q3'26 FCF resembles last year's ~$224M and buybacks run at the recent ~$400M pace, the deficit is roughly $0.38B, about half of last year's. That isn't proof, but it isn't the escalating leverage path you describe either. Interest cost on the $0.86B overspend is about 2% of net income, as we agreed.

4. The sizing argument assumes the only upside is 56.5¶

Your 0.8% figure counts the edge as 2.3% on one-third size. That treats the add trigger as the only upside from buying early. If the print is good, the stock may gap well past 56.5, and the starter captures that while waiting captures none of it. A bad print has the symmetric -13.6% risk. We both admit the skew is unseen, so the honest framing is a roughly symmetric bet at small size. That is not a strong argument for buying early, and I won't dress it up as one.

I'll add that the -13.6% precedent is one observation. It came from a stock near 46x trailing EPS, and the stock has since fallen another 7.8% on 7–21M-share days. Expectations are lower now, but I can't prove the bar is lower than the reality.

5. The unresolved items are less one-directional than you say¶

Viessmann: 12.09M shares is about 1.5% of the share count, and the stock was absorbing that around $62. No Form 4 after May 2026 appears in our data, though I can't verify vendor lag. That doesn't prove the stake is gone, but "he hasn't finished selling" is speculation either way.
The tape: it is bearish, and I'm not arguing otherwise. I'm arguing about price versus cash flow, not trend.
Data-center and order strength: retail posts only. It stays optionality.

Where this leaves us¶

Your bear case is much smaller than it was in round one. What remains is 24x FCF on falling earnings, a likely Q3 borrowing quarter, and a binary event with an unseen skew. My bull case is also smaller: real cash generation, a covered dividend, a stock that has already fallen 27%, and a price I'd call fair, not cheap.

My plan: - Starter: one-third size near $55. - Add: a close above ~56.5 on rising volume with OBV making a higher low than -87.22M, and only if the Q3 print isn't in the bad zone. - Exit: a close below 52.65, with no averaging down. - Trim: at 59.3–59.8. - Print rule: the revised gross margin and buyback tests above.

Waiting is a legitimate alternative, and I'd call the gap between us a preference about sequencing. What I'd resist is calling it a verdict. The data supports "not cheap, not broken, size small."

Data caveats: guidance, company news, the earnings date, peer multiples, repurchase prices and average volume were unavailable. The 94% conversion figure, the Q3 deficit estimate, the 24.3% scenario and the sizing percentages are my arithmetic from the tables, using D&A of ~$315M, SBC of ~$15M and 825M shares. Bull Analyst: # Bull Closing for CARR ($55.22): Tighten the Rules, Keep the Position Small

Your critique of my rules is mostly right. Here is what I'm fixing, what I think the full-cycle numbers actually show, and where I still disagree.

What I concede¶

The gross-margin zones were too loose. A 24.5% print (-150 bp) is nearly a repeat of Q2, and my rule would have said "hold."
The year-end debt test used the wrong base. June's $1.64B is the seasonal peak. Year-end 2025 current debt was $468M. The test also resolves after Q4, and it depends on "management's stated pace," which our tools don't have.
The seasonal-financing claim fails on the full-cycle net. Q3'25 through Q2'26 nets to -$863M, and the surplus quarters repaid only about a third of the deficits.
The buyback pace hasn't flexed to cash. Q3'25 ($785M) and Q1'26 ($306M) both ran well above FCF.
My stops can't act before a gap. If a rule fires at the print, the exit comes at the gapped price. Position size is the only protection against that.
The starter has no technical support. The case for it is valuation and cash flow, nothing else.

1. The buyback gap is concentrated in one quarter¶

The four-quarter net of -$863M includes Q3'25 at -$754M, which is 87% of the total. The three most recent quarters net to:

+$241M − $522M + $172M = −$109M

That is close to self-funded. It is also selective, because I'm dropping the worst quarter. Whether the improvement is real or just a different slice of the data comes down to Q3'26.

If Q3 FCF is about $224M, dividends about $193M and buybacks about $400M, the deficit is roughly -$370M.
That would roll off -$754M and put the trailing four-quarter gap near -$480M, about 45% smaller. These are my assumptions, not company guidance.

You're right that the pace didn't flex to cash in the past. The Q3 buyback line is the first test of whether it is starting to.

2. The gross-margin line is worth a lot of EPS¶

I said the whole debate sits in the 170 bp. That is why it matters so much. As an illustration:

170 bp on TTM revenue of about $22.1B is roughly $375M of gross profit.
After about 25% tax, that is about $280M, or about $0.34 a share on 825M shares.
Against TTM EPS of $1.44, that is about 24%.

This is a sensitivity, not a forecast. We only observe the compression in Q2, and I still can't diagnose whether it came from price, mix or input cost. But the gross-margin line carries more of the thesis than anything else, and the stock now trades at 24x FCF with a 4.2% yield and a dividend covered 2.5x. You're right that a holder earns the yield plus FCF growth, and growth has been negative. The bull case is that the current price doesn't require that growth to be positive, only for it to stop falling.

3. Revised rules, using only data the print will show¶

Q3'26 result	Action
Gross margin ≥26.0% and operating income above Q3'25's $495M	Thesis confirmed. Add on price confirmation.
Gross margin 25.0–26.0% (compression ≤100 bp)	Hold the starter. No add. Trim at 59.3–59.8.
Gross margin <25.0% (≥100 bp compression), or operating income below $495M on higher revenue	Cut. Negative incremental margin is a failure of the thesis.
Q3 buybacks well below Q3'25's $785M, near or below $400M	Pass.
Q3 buybacks at or above Q2's $439M with FCF around $224M	Fail. No add.
Year-end 2026 net debt at or below year-end 2025	Fix: this replaces the June comparison. That figure isn't in my pull, and I'd retrieve it.

The middle zone is now narrower, and the operating-income test is binary. Everything except the year-end net-debt test resolves at the print.

4. Where I still disagree: "zero edge"¶

You say the starter is a zero-edge bet against uniformly negative trend evidence. I'd say the edge is small and unquantifiable, which isn't the same as zero.

You conceded that 24x isn't flattered by working capital, the dividend is covered, and the overspend isn't a solvency story.
The tape has been negative for seven weeks, but that is also what a lower price already reflects. Momentum is a real effect. I can't measure it from this data, and neither can you.
A bet with a small, unmeasurable edge and a symmetric unseen skew is what a one-third position is for.

Your alternative is legitimate. If you need confirmation before you own it, waiting costs you part of a good-print gap and saves you the same size on a bad one. That is a preference, and I don't claim it is wrong.

Where it lands¶

Bull plan: - Starter: one-third size near $55. If you want less event risk, a quarter is defensible. - Add: a close above ~56.5 on rising volume with OBV making a higher low than -87.22M, only if the print isn't in the cut zone. - Exit: a close below 52.65, with no averaging down. A gap through it is the accepted cost. - Trim: at 59.3–59.8. - Print rules: as in the table above.

What I'm claiming: the business generates real cash, the price is fair rather than cheap, and the main risk is a margin line we can't yet explain. It is not a "mispriced" call. A small starter is the proportionate way to take that view, and the Q3 print will show whether to add or cut.

What would prove me wrong: Q3 gross margin below 25.0%, operating income below $495M on higher revenue, or buybacks held at Q2's pace with FCF near $224M.

Data caveats: guidance, company news, the earnings date, peer multiples, repurchase prices and average volume were unavailable. The -$109M three-quarter net, the -$370M and -$480M Q3 projections, and the $375M/$0.34 sensitivity are my arithmetic from the tables. They assume about $400M of Q3 buybacks, Q3 FCF near last year's $224M, a 25% tax rate, 825M shares and TTM revenue of $22.1B. The 25.0% and $495M thresholds are my own proposed lines, not company data.

Bear Researcher¶

Bear Analyst: # Bear Case for CARR ($55.22): The Buyback Is the Load-Bearing Wall

You closed by asking whether the real problem is the margin trend, the balance sheet, or a broken chart. It's all three, and they are one problem. Margins are shrinking, free cash flow doesn't cover the payout, commercial paper funds the gap, and the chart is the market noticing.

My thesis: CARR is a levered, margin-compressing cyclical. Its per-share story depends on debt-funded buybacks. At about 38x TTM EPS and about 36x EV/EBIT, it isn't cheap. The bounce is unconfirmed and the "defined risk" isn't defined.

1. Seasonality doesn't excuse the multiple¶

TTM EPS of $1.44 is four consecutive quarters (Q3'25 to Q2'26), one full seasonal cycle. The trough is in the number every year, so you can't call it distortion.

TTM is also generous: - Q4'25 and Q1'26 carried tax provisions of -$32M and -$96M. - In Q4, net income was $53M on $54M of operating income, despite $115M+ of quarterly interest expense. Tax benefits and equity income bridged that gap. - True earnings power is below $1.44, so the real multiple is above 38x.

On your own market cap, EV is about $45.6B + $10.6B net debt, roughly $56B. TTM operating income is $495M + $54M + $240M + $770M ≈ $1.56B, which gives about 36x EV/EBIT. I also can't verify "service and aftermarket" strength. Nothing in our data shows service mix, and a service-rich franchise doesn't usually lose 170 bp of gross margin on 3.9% growth.

You also used seasonality selectively. You dismissed it for the multiple, then cited "operating margin recovered from 4.5% to 12.1%," which is a seasonal sequential comparison. The like-for-like figure is 13.0% to 12.1%.

2. "Operating profit is roughly flat" isn't what the Q2 numbers show¶

Revenue rose $238M year over year. Gross profit fell $41M, operating income fell $25M, and EBITDA fell $83M. Growth that produces negative incremental margin is not flat.

Below the line, equity income fell to $58M from $78M and interest expense rose to $126M from $115M. Net income fell 15.2% despite a 3.4% lower share count.

3. The payout is the real problem¶

TTM cash returned was $2.79B, against $1.93B of FCF (145%) and $1.22B of net income (229%).
Your "~6% shareholder yield" adds the FCF yield to the dividend yield, which double-counts, because dividends come out of FCF. The real 6.1% is the cash actually returned, and it exceeds FCF.
The $860M gap was funded by commercial paper adds of $371M and $444M plus cash drawdown. Current debt went from $468M to $1.64B in six months, working capital fell from $1.42B to $183M, and common equity is down about 11% year over year.
This is as of June 30, the seasonally strongest cash point, right after an $810M FCF quarter.

Your two defenses contradict each other. You cite the 3% share-count decline as an EPS cushion, then say buybacks are discretionary and can be slowed. Slowing them removes the cushion. Diluted EPS fell 11.8% with it, against a 15.2% drop in net income.

Treasury stock rose about $2.05B, mostly at prices above today's $55. The director sales printed at $62 and $70, and the peak was $75.73. That is capital destroyed with borrowed money.

The $815M of held-for-sale assets doesn't fix this either: - The balance has grown from $592M to $621M to $815M, so deals are accumulating, not closing. - Even at full book value, it roughly equals one year of overspend. It would refill the hole, not delever.

Tangible book is -$7.9B, so there is no asset floor. The equity is purely a claim on earnings that are currently shrinking.

4. Insiders¶

The CEO's buy was $1.02M. The director sold about $1.05B, roughly a 1,000:1 ratio.
The 19,300 shares Gitlin bought equal about 21% of his January grant of 90,872 shares.
I see no purchase after the 27% drop, in the data we have.
Viessmann's second sale was at $62 versus $70 for the first, and his remaining stake is unknown. The overhang is unresolved.

I'll concede that his sale isn't a timing signal, since the stock ran to $75.73 afterward. It is still supply.

5. The chart doesn't show a washout¶

Capitulation looks retrofitted. RSI was 27.0 on 09-01 at $57.25, and the stock then fell another 5.9%. Oversold got more oversold.
OBV hit a lower low on 09-30 (-87.2M), eight sessions after the "capitulation." A real washout ends with a higher OBV low.
The bounce is thin. On 10/1 CARR rose +0.66% on 7.4M shares, about a third of 09-18's 21.4M, and closed below its 10 EMA (55.43). That was on a day when, per headlines, the whole tape rebounded.
Highs are falling. Closes ran 56.37, 55.87, 55.38, 54.86, 55.22. The MACD histogram has stalled at 0.24–0.27, and the range low of 54.00 came on 10/1.
Your targets are resistance, not reversal. All three SuperTrend tiers are down, and the weekly flip level is 68.06, +23% away. The 50 SMA is still falling.
"Defined risk" isn't defined. On 07-28 the stock gapped -8.9%, then fell another -5.1% the next day. That is -13.6% in two sessions on 33M shares. A stop 4.7% away doesn't protect against that. Using the report's 2x ATR stop (~52.1), reward to 59.3 is about 1.3:1.
The put flow. You can't call it unverified and then use it as evidence of support. If it's real and customer-bought, dealer hedging adds selling pressure near $52, which works against the "floor." I don't lean on it either.

6. Macro¶

The "yields fell" read comes from headlines only. The same feed carries Fed officials saying inflation is "still too high" and Gundlach's "hollow tree" warning. I wouldn't build a thesis on that mix for a rate-sensitive building products name.

Where you have a point¶

Q2 FCF of $810M and +3.9% revenue are real.
The Q3'25 FCF comp is easy at $224M, so a year-over-year Q3 FCF gain proves little.
The stock could bounce into 59–60. My objection is to risk/reward, not the possibility of a rally.

Your own kill criteria¶

Debt-funded buybacks: this has already happened. In Q3'25, $978M went out against $224M of FCF. In Q1'26, $507M went out against -$15M.
Q3 gross margin: the bar is 26.0% after a 170 bp year-over-year compression in Q2, with no evidence of an inflection.
A close below 52.65: this is 4.7% away.

What would change my mind¶

Q3 gross margin at or above 26.0% with positive incremental operating margin.
Buybacks cut to FCF minus dividends, or held-for-sale proceeds applied to the commercial paper.
A close above ~56.5 on rising volume, with OBV making a higher low and RSI above 50.

Data gaps: guidance, news, the earnings date and service mix were unavailable, and I've tried not to fill them with guesses. Where does that leave a buyer? The cash flow doesn't cover the payout, margins are compressing, and there is no volume confirmation. The Q3 print is probably within weeks. I'd wait for it, and anyone long should treat 59.3–59.8 as a place to sell, not a target to hold for. Bear Analyst: # Bear Reply for CARR ($55.22): Your Thesis Now Rests on a Line You Say You Can't See

You gave up a lot, so I'll start with what I'm giving up.

What I concede¶

You're right on the 158%. TTM FCF of $1.93B over net income of $1.22B is 158%. The report's 88% doesn't reconcile, and I'm dropping it.
TTM FCF isn't flattered by working capital. TTM operating cash flow is $2.39B, versus roughly $2.5B for net income plus D&A plus SBC. Working capital and other items were a drag of about $150M. Your caveat resolves in your favor, and 24x price to FCF is the fair cash multiple. I'll stop leaning on 36–38x.
7.4M against 21.4M of volume proves nothing, because we have no average volume. The test is OBV making a higher low than -87.22M.
The 10/1 close of 55.22, two cents under the high, was a strong close. I also agree negative tangible book is mostly a goodwill artifact, and that the CEO's $1M buy and the director's $1.05B sale aren't like for like. Blackout windows make the lack of insider buying weak evidence.

1. 24x FCF is the right lens, and it still isn't cheap¶

A 4.2% FCF yield on a business whose EBITDA fell 6.7% and EPS fell 11.8% needs growth to pay off. Revenue is growing 3.9% and margins are shrinking.

The Q2 FCF jump you led with doesn't come from earnings either: - Q2 FCF rose $242M year over year, with operating cash flow up $278M. - Net income fell $90M, and D&A was steady at about $315M. - That implies roughly $370M of favorable swing in non-earnings items. This is my arithmetic from the tables.

"Cash generative" is true over a full year. The year-over-year improvement was timing, not operating strength.

2. "Already priced" doesn't survive the numbers¶

You say $17B of market cap is gone against a $25M drop in quarterly operating income. That is mostly de-rating. - At the $75.73 peak, TTM EPS was $1.52 (0.68 + 0.50 + 0.06 + 0.28), so the stock traded near 50x. - It is now about 38x, still a premium multiple on shrinking EPS. We have no peer multiples, so I can't call it out of line with peers. - If the July print was the catalyst, the stock closed at 59.92 on 07-29. It has since fallen another 7.8%. The market kept marking down for seven weeks after the print, which is not what a fully discounted bad quarter looks like.

3. The buyback is cheap to give up only if gross margin holds¶

You've said the thesis is margin and cash conversion, and that gross margin "carries the load." You've also said you can't diagnose the 170 bp and can't tell whether it is widening or narrowing. That is a thesis resting on a variable you can't observe.

Your self-funded buyback math is right (about $1.15B against $2.01B spent). But:

Repurchase prices: share count gives a bound. The net share reduction was 25.8M for $2.01B, which implies at most about $78 a share. Even allowing several million shares of issuance, the average is in the mid-$60s or higher. That is an inference, and the vendor flagged a share-data inconsistency. The Q2'26 buyback of $439M was almost certainly done in the $60s and $70s.
Carrying cost: the $0.86B overspend costs roughly 4% a year. That rate is Q2 interest expense annualized over $12.4B of debt. It comes to about $25–35M a year, roughly 2% of net income. Part of your 3.4-point EPS cushion is already being paid back in interest.
Your balance-sheet test fails by arithmetic in Q3.
Q3'25 FCF was $224M against $193M of dividends, which left $31M.
At the Q1–Q2 buyback pace of $306–439M, Q3'26 needs about $500–640M of FCF just to avoid new borrowing. That is more than twice last year's Q3.
Unless buybacks are cut, current debt rises again.

4. "The damage sits in one line" is the top of a waterfall¶

Gross profit is down $41M, operating income is down $25M, EBITDA is down $83M, net income is down $90M, and EPS is down 11.8%, all on revenue up 3.9%. - Opex fell $16M, which recovered only 39% of the gross profit shortfall. Cost cuts have a ceiling, and I don't know where this one is. - Your own decomposition leaves a gap. EBITDA minus operating income fell $58M, and equity income explains only $20M. Assuming flat D&A, about $38M is unidentified. - The below-the-line items you list (equity income, interest, tax rate, minority interest) are costs to shareholders whether or not you call them operating.

5. The starter position is the one part of your plan that isn't rule-based¶

Your rules are to confirm above 56.4–56.5 on volume, then add, and invalidate below 52.65. A starter position before the print breaks the first rule by design.

Its payoff through the print isn't 1.3–1.6:1. The only observed print reaction is -13.6%, against a first target of +7.4%. A repeat of that gap is about 2.9 times your stop distance (4.65%) on the position you hold. A good print could gap up too, and I can't tell you the skew. Neither can you, since guidance isn't in our data. That is a reason to wait, not to size for it.

Waiting costs me part of an upside gap if the print is good. I accept that.

Where this leaves us¶

You asked what's left of the bear thesis if the three conditions arrive. My conditions were broader than the version you restated. You dropped: - positive incremental operating margin; - OBV making a higher low with RSI above 50; - held-for-sale proceeds applied to commercial paper.

If Q3 gross margin is at or above 26.0% with positive incremental margin, buybacks are cut to self-funded, and price confirms, I move to neutral or constructive. That is a different stock from the one we're debating.

What would remain is valuation. That is 24x FCF and about 36x EBIT with the buyback tailwind gone, plus the unresolved Viessmann overhang. That is a smaller bear case but not zero.

The dispute is about sequence. Every one of those tests resolves within weeks. Waiting for them costs a few points. Owning through an unseen guidance event, with a -13.6% precedent, risks more than that.

My position is no purchase at $55.22. Anyone long should treat 59.3–59.8 as a place to sell. Q3 gross margin and the buyback decision are the two numbers that would move me.

Data caveats: guidance, news, the earnings date, peer multiples, service mix, repurchase prices and average volume were unavailable. The repurchase-price bound, the $370M swing and the $38M gap are my inferences from the tables, with D&A held flat. Bear Analyst: # Bear Reply for CARR ($55.22): Your Own Exit Rules Are Likely to Fire at the Print

You've narrowed this to one question: should anyone own CARR into the Q3 print? Your plan answers it against itself.

What I concede¶

The Q2 OCF decomposition is right. Q2'26 operating cash flow was about 111% of net income plus D&A plus SBC, and Q2'25 was about 70%. Q2'26 wasn't flattered.
The carrying cost of the overspend is small. At about 2% of net income, this isn't a solvency story, and I'm not calling it one.
The starter position is a staged rule, not a rule-free one.
Waiting may cost me part of a gap up. I accept that.

1. Your FCF de-rating argument proves my point¶

You say the stock de-rated from 37x to 24x FCF while trailing FCF rose 14%. But we agree that the rise came from Q2'25 normalizing, a $568M quarter replaced by an $810M one. That is a comp effect, not operating improvement.

Over the same window: - TTM EPS fell from $1.52 to $1.44. - EBITDA fell 6.7% in the latest quarter. - Operating income fell 3.1% on revenue up 3.9%.

FCF rose on a comp while earnings fell. That is not a cash-generation story getting cheaper. You also compared 24x FCF today to the roughly 50x P/E at the peak. On one metric, the stock was about 46x EPS at the 07-28 gap price ($69.33) and is about 38x now. On FCF it was about 34x and is about 24x. Neither is a bargain on shrinking earnings.

2. Your cut rules are likely to fire at the print¶

Your rule is to cut if Q3 gross margin is below 26.0%, or if current debt keeps rising with buybacks unchanged.

Gross margin. Q3'25 was 26.0%, and the only year-over-year datapoint we have is -170 bp. Your rule fires on any decline, and a repeat of Q2 would put Q3 near 24.3%. You've also said you can't tell whether the compression is narrowing.
Debt. You conceded that Q3 needs $500–640M of FCF at the Q1–Q2 buyback pace, against $224M last year. The rule fires unless management cuts buybacks, and the pace re-accelerated from $306M to $439M in Q2. That quarter's repurchases were probably done in the $60s and $70s.

If a rule is likely to trigger at an event, you aren't managing risk by holding through it. You are betting that the data inflects without any evidence that it will. And "cut rather than argue with the tape" means cutting after the gap, at the gapped price.

3. The starter sizing doesn't fix the payoff¶

A one-third position cuts the loss on another -13.6% gap to about 4.5% of a full position. It cuts the gain to the first target (+7.4%) to about 2.5%, so the ratio is the same. Sizing changes how much you lose, not whether the bet is good.

You've also said your edge is "entry price relative to the confirmation levels, not a mispricing." Your add trigger is about 56.5, only 2.3% above today. That is the whole edge from buying before confirmation, about 0.8% of a full position on a one-third starter. The cost of buying early is exposure to a binary event whose last observed outcome was -13.6%, and whose skew neither of us can see.

4. The unresolved items point the same way¶

The Viessmann overhang. You say the capitulation could be supply rather than repricing. Either reading is a reason to wait. Fundamental repricing isn't finished, or a $750M seller with an unknown remaining stake hasn't finished selling.
The buyback. "Cheaper stock retires more shares" is true. It is also an argument for management to buy more with commercial paper into falling EPS, and that is the leverage path I'm worried about.
The tape. All three SuperTrend tiers are down, the stock is below both the 50 and 200 SMAs, and OBV made a lower low on 09-30. Nothing in the technicals supports early entry.
The data-center and order-strength thesis is retail posts only. It is optionality, as you say, not evidence.

Where this leaves us¶

You have a reasonable plan for someone who wants exposure, but it is built around an event you can't forecast. The earnings date isn't in our data. July 28 suggests late October, but that is inference.

My position: - No purchase at $55.22. - Anyone long should treat 59.3–59.8 as a place to sell. - I'd revisit after the print if Q3 gross margin is at or above 26.0% with positive incremental margin, buybacks are cut to roughly FCF minus dividends, and price closes above about 56.5 on rising volume with OBV making a higher low than -87.22M.

The bear case is smaller than it was three rounds ago. What remains is 24x FCF on falling earnings, a buyback that is likely to need new borrowing in Q3, and a binary event with a -13.6% precedent. That is enough to wait.

Data caveats: guidance, news, the earnings date, peer multiples, repurchase prices and average volume were unavailable. The 46x and 34x figures, the 24.3% Q3 gross margin scenario and the 0.8% and 2.5% sizing figures are my arithmetic from the tables, assuming 825M shares and the D&A and SBC inputs we've both used. Bear Analyst: # Bear Reply for CARR ($55.22): Your Revised Rules Now Almost Never Say "Cut"

Your last round fixed the rule that misfired, and I'll credit that. But the fix removed most of the rule's content. Most of what remains between us is whether a coin-flip bet is worth holding when waiting costs little.

What I concede¶

Viessmann is weak evidence. He sold 12.09M shares at $62.01 on 05-20, the stock ran to $75.73 within five weeks, and I can't verify his remaining stake. "He hasn't finished selling" is speculation, so I'm dropping it as a pillar. It is unresolved supply risk, nothing more.
The -13.6% is one observation, and the July print attribution is my inference. It tells us the scale of a gap, not its direction.
Your Q3 deficit arithmetic is right. $224M of FCF, less $193M of dividends, less about $400M of buybacks leaves roughly -$370M. That is about half of Q3'25's -$754M.
The sizing framing is honest. A one-third starter is a roughly symmetric bet with an unseen skew.
FCF quality. TTM operating cash flow at about 94% of net income plus D&A plus SBC means the 24x isn't flattered. We now agree on that number.

1. The revised gross-margin rule says "hold" for almost every realistic outcome¶

Your zones are: - At or above 26.0%: confirmed. - 24.3–26.0%: hold the starter. - At or below 24.3%: cut.

The middle zone spans year-over-year compression from 0 to 169 bp. Q2 compressed 170 bp, and that compression is the whole debate. A Q3 gross margin of 24.5% would be -150 bp, nearly the same problem, and your rule calls it "narrowing" and holds. It cuts only if Q3 is worse than Q2 was, and that outcome would likely arrive with a gap. A stop can't act before a gap, so the cut executes at the gapped price.

You've also said EPS is still falling in the middle zone. The likely outcome is therefore that you hold a position into declining earnings, with no cut signal.

2. The buyback test is both too easy and not testable at the print¶

Wrong comparison base. You'd judge year-end debt against June's $1.64B. But current debt was $468M at year-end 2025. Q4 is a $900M-FCF quarter, so year-end debt is seasonally low, and June is not the right yardstick. Year-end 2026 current debt of $1.2B would "pass" your test while being 2.5x last year-end.
Timing. It resolves after the Q4 report, not at the Q3 print.
Data. "Management's stated pace" is guidance, which our tools don't have. We can't score the rule with what we hold.

3. "Seasonal financing" fails on the full-cycle number¶

If buybacks were seasonal financing, the surplus quarters would repay the deficit quarters. Your own quarterly figures:

Quarter	FCF minus dividends and buybacks
Q3'25	-$754M
Q4'25	+$241M
Q1'26	-$522M
Q2'26	+$172M
Net	-$863M

A full cycle already contains Q2 and Q4. The surplus quarters repaid about a third of the deficit, and the rest was funded by commercial paper and cash drawdown. Seasonality explains the quarterly shape, not the net.

The pattern also isn't "buy in cash-rich quarters." The two cash-rich quarters had buybacks of $479M and $439M, and the weakest-FCF quarter, Q3'25, had $785M. Even with negative FCF in Q1'26, buybacks didn't go below $306M. The pace hasn't flexed to cash. I agree it isn't a solvency story. It is a policy that has required new borrowing in two of the last four quarters, and one more is likely in Q3.

4. The sizing concession is my argument¶

You wrote that this is "a roughly symmetric bet at small size" and "not a strong argument for buying early." I agree. Then the question is what justifies holding it:

Technicals: you concede the starter has none. All three SuperTrend tiers are down, price is below the 50 and 200 SMAs, and OBV made a lower low on 09-30.
Valuation: 24x FCF, which you call "fair, not cheap."
Fundamentals: operating income is -3.1% and EPS is -11.8% on 3.9% revenue growth.

A zero-edge bet against uniformly negative trend evidence is a reason to wait. I can't quantify how predictive the trend is, and I won't pretend to. But the only market-implied read on the print's skew in our data is the tape, and it has been negative for seven weeks since July 29.

What waiting costs is the starter's share of a good-print gap. I accept that, and it is bounded. The cost of holding is the same size on the other side, with no edge to offset it.

5. The "24x isn't paying for failed growth" point¶

At a 4.2% FCF yield, a holder's return is that yield plus FCF growth. TTM FCF is at a good level, but the trailing growth we can observe is operating income down 3.1% and EPS down 11.8%. A fully self-funded payout would be about $1.15B of buybacks, about 2.5% of market cap, plus the 1.7% dividend. That is a fair business at a fair price, and fair doesn't compensate for the Q3 event risk.

Where we actually stand¶

"Not cheap, not broken, size small" is a fair summary, and I agree with two of those three words. "Not broken" is fair. The business generates real cash, and the dividend is covered about 2.5x. My disagreement is with the third word: size small doesn't change that the bet has no demonstrated edge, and the rules meant to limit it fire only after the damage.

My position: - No purchase at $55.22. - Anyone long should treat 59.3–59.8 as a place to sell. - Revisit after the print if Q3 gross margin is at or above 26.0% with positive incremental margin, buybacks are cut toward FCF minus dividends, and price closes above about 56.5 on rising volume with OBV making a higher low than -87.22M. Failing any of those, I'd keep waiting.

Data caveats: guidance, company news, the earnings date, peer multiples, repurchase prices and average volume were unavailable. The -$863M net, the -$370M Q3 deficit estimate, the hold-zone bp range and the 2.5% self-funded buyback figure are my arithmetic from the tables, using the same D&A and SBC inputs, 825M shares and $400M of Q3 buybacks as assumptions. The date of the Q3 print is an inference from the July timing. Bear Analyst: # Bear Reply for CARR ($55.22): The Rules Are Better, and They Still Fire on Trend Continuation

Your table is a real improvement. It uses thresholds the print will show, closes the 24.5% loophole, and makes operating income binary. I'd accept most of it as my own re-entry framework. What's left is narrow.

What I concede¶

Your rules are testable. The gross-margin and operating-income rows resolve at the print.
The buyback gap isn't a solvency story. About $480M a year at a ~4% cost of debt is roughly $19M, under 2% of net income.
Zero edge was too strong. "Small and unquantifiable" is fairer.
Waiting may cost me part of a good-print gap. I accept that.

1. The -$109M figure is selective, and the right comparison is worse¶

You flagged the selectivity yourself. The better point is that every trailing year contains a Q3, so dropping it isn't a like-for-like improvement. Your own projection is the honest number:

After Q3'26, the trailing four quarters net to about -$480M.
That is less bad than -$863M, but it isn't self-funded.
It also depends on Q3'25's -$754M rolling off, so the improvement is mostly a comp effect.

Your "pass" threshold has the same problem. Q3 buybacks of "near or below $400M" are the quarter that creates the -$370M deficit. Annualized, $400M a quarter is $1.6B against the $1.15B self-funded pace you computed earlier, about 40% above it. A "pass" that still requires new borrowing is a lower bar than the one you set two rounds ago.

A buyback "fail" also only blocks adding. It never triggers a cut, so the capital-allocation risk I care about cannot end your trade.

2. Your cut rule fires if Q2 simply repeats¶

I ran the print against your thresholds. These are my assumptions: revenue +3.9%, gross margin 170 bp below Q3'25's 26.0%, and opex trending down 1.6% as it did in Q2.

Revenue would be about $5.80B and gross margin about 24.3%.
Gross profit would be about $1.41B, against opex of about $939M.
Operating income would be about $470M, below your $495M line.

Both your gross-margin test (<25.0%) and your operating-income test fail in that case. To avoid a cut, compression has to narrow from 170 bp to under 100 bp, about 40% better than Q2. The data gives no evidence that this is happening, and you've said you can't diagnose the cause.

So the plan is to hold through an event where the only observed trend trips your own exit. You've conceded the exit then executes at the gapped price. Sizing limits the loss, but it doesn't make the bet better.

3. Two rows aren't scorable with our data¶

Year-end net debt: you said it isn't in your pull. It also resolves after the Q4 report, long after the print and long after the starter is on.
The 400–439M buyback band falls between your "pass" and "fail" rows and isn't covered.

These are smaller flaws than the rule you replaced, but they are gaps.

4. "Momentum is a real effect" doesn't help the starter¶

You said momentum is real and can't be measured here. The general finding, which is outside our data, is that intermediate-horizon losers tend to keep lagging. That works against a pre-print purchase. CARR has fallen about 27% from its June 25 high and made lower highs through September. There is also a short-horizon reversal effect, but the one-month move here is small, about -3.5% from 09-01. I'm not leaning on either effect, and I'd ask you not to count momentum as support.

5. The bull case is a flat-FCF case¶

You said the price doesn't need growth, only for it to stop falling. If it only stops, a holder earns about the 4.2% FCF yield. That return comes with 3.4x net leverage, a payout that has needed new borrowing in two of four quarters, and a print where your own exit rule fires on a repeat of Q2. I can't compare 4.2% to the risk-free rate, because the FRED pull failed and I won't guess. Even so, "fair price, no technical support, small edge" describes a position you'd hold only if you had a reason to prefer it to waiting.

Where this leaves us¶

We now agree on most of the framework.

Re-entry: Q3 gross margin at or above 26.0% with operating income above $495M, buybacks cut toward FCF minus dividends, and a close above ~56.5 on rising volume with OBV above -87.22M.
Invalidation: a close below 52.65, or a print in the cut zone.
The disagreement: whether a one-quarter-to-one-third starter before the print is worth it. You call it a proportionate way to hold a view. I call it a symmetric bet with no stated edge, and your rules fire on trend continuation.

My position: - No purchase at $55.22. - Anyone long should treat 59.3–59.8 as a place to sell. - After the print, I'd move to neutral or constructive if your "thesis confirmed" row prints and the buyback pace falls toward self-funded. If it lands in the hold zone, I'd keep waiting.

Data caveats: guidance, company news, the earnings date, peer multiples, repurchase prices, average volume, risk-free rates and year-end 2025 net debt were unavailable. The $470M operating income scenario, the 24.3% gross margin, the 40% narrowing requirement, the 40% buyback excess and the ~$19M carrying cost are my arithmetic from the tables. They assume revenue +3.9%, opex -1.6% as in Q2, a ~4% cost of debt and $400M of Q3 buybacks. The momentum comments are general market knowledge, not CARR data.

Research Manager¶

Recommendation: Underweight

Rationale: The debate narrowed a lot, and most of the narrowing went the bear's way. By the last round, the bull had conceded that the 38x P/E and 36x EV/EBIT can't be explained away by seasonality. He also conceded the 6% shareholder-yield double-count, that operating income fell 3.1% on +3.9% revenue, that the buyback has been debt-funded over the full cycle (-$863M net over four quarters), that his 'seasonal financing' framing fails, and that the starter position has no technical support. The bull's surviving case is real: TTM FCF of $1.93B isn't flattered by working capital (OCF is about 94% of NI+D&A+SBC), the dividend is covered about 2.5x, the overspend costs under 2% of net income, so there's no solvency issue, and 24x FCF is fair. But he describes it himself as 'fair, not cheap' with a 'small, unquantifiable edge' and a 'roughly symmetric bet.' That isn't enough to own a cyclical into a binary print.

Three bear arguments decided it. First, the bull's own revised cut rules (gross margin below 25.0% or operating income below $495M) fire if Q2's 170 bp compression simply repeats. The bear's scenario puts Q3 operating income near $470M. To avoid a cut, compression has to narrow by about 40% with no evidence that it is narrowing, and neither side can explain why it's happening. A stop can't act before a gap, and the only observed print reaction was -13.6% over two days. Second, the trend evidence all points one way: the stock is below the 50 and 200 SMAs, all three SuperTrend tiers are down, OBV made a lower low on 09-30 after the supposed capitulation, and the stock kept falling 7.8% for seven weeks after the July gap. Third, capital allocation hasn't flexed to cash. Even the bull's 'pass' threshold of about $400M a quarter in buybacks runs about 40% above the self-funded pace, so another commercial-paper-funded quarter is likely in Q3.

Why not Sell: the business isn't broken. Cash generation is real over a full cycle, leverage of about 3.4x with about 3.8x interest coverage is manageable, the stock is already down about 27% from its peak, and a good print could gap it up. The bear's own position is 'wait and sell into strength,' not 'exit at any price.' Data gaps cut both ways: no guidance, no news, no earnings date, no peer multiples, no repurchase prices, no average volume. That uncertainty argues for less event exposure rather than a high-conviction short. Net: a cautious, reduced-exposure stance with a clear re-entry framework.

Strategic Actions: 1) No new purchases at ~$55.22, and no pre-print starter. 2) Existing holders: reduce to about 0.5x standard allocation before the Q3 print, which is likely late October based on July timing (unconfirmed). Do the trimming into strength: sell part on any move to ~56.5, and the rest of the reduction at the 59.3–59.8 resistance cluster. Treat that zone as a sell zone, not a target to hold for. If the stock hasn't bounced by about a week before the expected print date, complete the trim at market. 3) Hard risk line: a daily close below 52.65 means exiting the remaining position. Don't average down. Assume gap risk of up to about 14% on the residual. 4) Post-print scoring: (a) gross margin of 26.0% or more AND operating income above $495M AND Q3 buybacks cut toward self-funded (about $290M a quarter, i.e. FCF minus dividends, and clearly below $400M) → rebuild toward full weight, adding only on a close above ~56.5 on rising volume with OBV making a higher low than -87.22M; (b) gross margin 25.0–26.0% with no operating-income miss → hold at 0.5x and keep trimming at 59.3–59.8; © gross margin below 25.0%, OR operating income below $495M on higher revenue, OR buybacks of $439M or more with FCF near $224M → exit the rest. 5) Monitoring: Form 4s for further Viessmann sales, the current-debt trend versus the $468M at year-end 2025, and any held-for-sale proceeds applied to commercial paper. Retrieve guidance and the confirmed earnings date before the print, because that data was missing from this analysis.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan is Underweight, which maps to Sell as a sized reduction rather than a full exit. The trend is bearish on every tier: price is below the 50 SMA (59.77) and 200 SMA (61.32), all three SuperTrend tiers are down, and OBV made a lower low on 09-30, so the bounce has no volume support. The bull's own cut rules (gross margin below 25.0% or operating income below $495M) would trigger if Q2's 170 bp margin compression repeats. Buybacks are debt-funded and the Q3 print is a binary event with gap risk, so the plan trims into strength at 56.5 and the 59.3–59.8 cluster. It is not a full exit because cash generation is real, leverage is manageable, and the stock is already about 27% off its peak.

Entry Price: 56.5

Stop Loss: 52.65

Position Sizing: Reduce existing holdings to about 0.5x standard allocation before the Q3 print, which is likely late October and unconfirmed. Sell the first part near 56.5 and the rest of the reduction at 59.3–59.8. If there has been no bounce about a week before the print, complete the trim at market. Exit the remaining position on a daily close below 52.65. Do not add or average down. Make no new purchases at 55.22. Assume gap risk of up to about 14% on the residual. Portfolio context was not provided, so apply these as relative changes to the current position.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Since nobody has spoken yet, I'll open the debate and answer the objections I expect.

The Sell is the bold call here. Underweighting a stock that has already lost about 27% takes conviction. The easy move is to hold and hope, or to buy because it looks cheap. I think that easy move is the one that gets punished.

The first objection I expect is that CARR is already down from 75.73 to 55.22 and we'd be selling the bottom. The data doesn't say that. RSI is 39.9, not oversold anymore. The weekly z-score is -1.47 and the daily is -0.53, so nothing is at a statistical extreme. Price sits in the lower half of the Bollinger range, not at the band. The plan also doesn't sell the low. It sells into strength at 56.5 and the 59.3 to 59.8 cluster, where the daily SuperTrend stop, the upper band and the 50 SMA all stack up. If the bounce never comes, the fallback is to complete the trim at market a week before the print. The plan doesn't need a bounce to work.

The second objection is that September looked like capitulation, with 21.4M shares on 09-18, so the worst is behind us. But OBV made a lower low at -87.22M on 09-30 while price was higher than on 09-18. That means volume kept leaving even as price stabilized. The death cross printed on 09-24, and all three SuperTrend tiers are down. Weekly and monthly flips would take a rally to 68 or 76, so no one is calling a reversal here. A MACD histogram stuck at +0.25 for three sessions is a stall, not a turn.

The fundamentals are where holding full size gets hard to defend. The bull's own cut rules are gross margin below 25.0% or operating income below $495M. Q2 showed 170 bp of gross margin compression year over year. Apply that to Q3'25's 26.0% and you get about 24.3%, below the line. Apply the 90 bp operating margin decline to Q3'25 revenue grown 3.9% and you get roughly $465M of operating income, below $495M. That's my own back-of-envelope arithmetic, but it shows the bull's thesis breaks if Q2's pattern merely repeats.

The balance sheet adds fuel. Net debt is $10.6B, about 3.4x TTM EBITDA. Short-term debt jumped from $468M to $1.64B. Working capital is $183M. Buybacks plus dividends ran about $0.86B ahead of free cash flow over the last year, so the buyback is partly debt-funded. Free cash flow of about $1.93B on roughly 825M shares at 55.22 is a yield near 4%. That's decent, not a margin of safety.

Then there's gap risk. The 07-28 and 07-29 drop took the stock from 69.33 to 59.92, about 13.6% in two sessions. The tools don't name the cause, but the timing fits a quarterly print. So the 14% gap assumption comes from this stock's own recent behavior. At full size that gap is a 14% hit. At 0.5x it's about 7% of the original position's value, and the residual still keeps upside if Q3 surprises.

The conservative case may be to exit entirely. I disagree. Cash generation is real, leverage is manageable, there's $815M of held-for-sale assets that could fund deleveraging, and the CEO bought about $1M of stock at 52.62. Dumping everything risks being wrong in the other direction, and the 52.65 daily-close stop covers the residual. The 52.65 stop sits almost exactly on the CEO's purchase price and the lower Bollinger band. If management's own cost basis fails, I don't want to be there.

The neutral case is probably to hold until the print gives clarity. But that waits for a binary event with negative skew: a technical downtrend, a margin trigger likely to be hit, and director Viessmann having sold about $1.05B of stock over 12 months. The cost of waiting is fully exposed gap risk. The cost of trimming is giving up some upside on a stock that hasn't confirmed a single bullish signal. I'll take that trade.

On sentiment, I won't oversell it. Six StockTwits messages is nothing, and the $1.6M put print at the $52 strike is unverified and could be a hedge. I'm leaving it out of the thesis. Retail is split, which is what you'd expect at an inflection with no edge.

I should be honest about what we don't have. We don't know the portfolio, the earnings date is unconfirmed, there's no guidance, no valuation multiples, and no usable macro data beyond headlines. That's why this is a sized reduction, not a full exit. Trim to 0.5x, sell into 56.5 and 59.3 to 59.8, finish the job at market if no bounce shows by a week before the print, and exit the rest on a daily close below 52.65. Don't average down. The free capital is worth more waiting for a confirmed setup than sitting in a falling stock with negative OBV. Aggressive Analyst: I'll start with where you've both landed a clean punch, because conceding those points makes the rest of my argument stronger.

The conservative is right that the 59.3 to 59.8 tranche can't be the plan. It needs a 7 to 8 percent rally in a stock with a death cross and a lower low in OBV, so I'm demoting it to a bonus resting order. The neutral is right that "a week before the print" hangs on a date none of us has confirmed, so the backstop should be the earlier of mid-October or a week before the confirmed date. Both of you are also right about the CEO. His $52.62 purchase is eleven months old and predates Q4, Q1 and the Q2 compression. The overlap with the 52.65 lower band is a coincidence, and I shouldn't have leaned on it. These changes make the Sell tighter without making it more timid.

Now for where I push back. Conservative, selling the bulk right now at 55.22 trades a small gain in certainty for a worse price. The stock sits just under its 10 EMA, in the middle of a closing range that has held for eight sessions since a 21M-share capitulation day. The neutral's fix is better: the gap between 55.22 and 56.5 is about 2 percent, so work limits from 55.5 to 56.4 starting now. That gets most of the early reduction done without paying for urgency.

On going below 0.5x or hedging the residual, I disagree. We have no implied volatility data, no knowledge of whether the caller trades options, and a reported $1.6M of puts around the 10/30 expiry that suggests protection isn't cheap. Making a hedge a requirement turns a sizing decision into an execution problem. The residual exists to keep upside if Q3 surprises, and cutting it further gives that up for little. If the caller can collar it cheaply, fine, but that's optional.

On the gap, the conservative made a fair point that 14 percent comes from one observation. But the same data cuts against the neutral's claim that some of this is priced in. The stock gapped to 59.92 after the late July drop and then fell another 10 percent, to 53.88. If the market had finished repricing Q2's margin compression, that drift wouldn't have happened. The first-day move was about 9 percent and the cumulative move from the pre-gap close was 22 percent. So size is the control, as the neutral said, and 0.5x is a sensible size given that range of outcomes.

On the stop, I'll keep the close-based version outside the event window. ATR is 1.56, and the 09-18 intraday low of 52.96 was only 31 cents above 52.65. An intraday stop would likely have been run on the exact day the stock found its low. Inside the print window, nothing protects us from a gap anyway, which is why the size and the deadline carry the weight.

I also don't want the neutral's softer read on Viessmann to go unchallenged. Calling it a supply overhang rather than an operating signal is accurate, but that's exactly why it matters for a price call. He sold $750M at 62.01 in May, and the stock is now 11 percent below that. A holder who sold at 70.30 a year earlier and 62.01 more recently has shown he'll sell into weakness, and nobody has told us the stake is gone.

The valuation arithmetic is the strongest support for being bold. Using 825M shares, market cap is roughly $45.5B, about 38 times trailing EPS and high-teens EV to EBITDA. Trailing numbers are depressed by the trough quarters, so I wouldn't lean on that too hard. But a stock down 27 percent that still trades there offers no margin of safety, and the cut rules sit close to breaking. Gross margin needs only 100 bp of compression to hit 25.0 percent, and Q2 showed 170. Operating income needs a margin decline of only about 35 bp on 3.9 percent revenue growth to fall under $495M. I'd call that a coin flip with a bearish tilt, as the neutral said, but the downside is a gap on a levered, buyback-dependent story, and the upside of being full size is a rebound in a stock that has confirmed nothing.

That's the core asymmetry. At 0.5x, a repeat of the late July gap costs roughly half what it would at full size. If Q3 surprises, the residual still participates, and the freed capital is available for a confirmed setup instead of sitting in a stock with negative OBV. Holding full size to see what happens is the choice with no cushion, and trimming is the choice with a cushion and real optionality.

So I'd take the amended plan. Look up the earnings date today. Work half the reduction through limits at 55.5 to 56.4 now. Complete the rest by the hard backstop. Keep a resting order at 59.3 to 59.8 as a bonus. Exit the residual on a daily close below 52.65, and don't add anywhere in this range. If the stock closes above 56.4 with OBV turning up and RSI over 50, sell into that strength anyway, because the risk comes from the print, not the chart.

My recommendation remains a Sell, executed as a sized reduction to about half of whatever the caller holds today.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Most of what's left between us is fine-tuning, so I'll concede the points where you're right and then defend the two places I'm holding.

Conservative, you're right that a 52.65 intraday stop wouldn't have triggered on 09-18, since the low was 52.96. I overreached there. The evidence supports a resting stop, just placed lower, around 52.3 to 52.4, under both the lower band and the swing low. That's about 2x ATR from here, and the stock has held above that zone since the capitulation day. I also used the put print to argue hedging is expensive right after saying I'd leave it out of the thesis. That was inconsistent. The honest reason hedging is optional is that we have no implied volatility and don't know the caller's options access.

Neutral, you caught me on valuation. I called it my strongest support and then said not to lean on it. It's only a reason not to call the stock cheap, and I'll leave it there. You're also right that Viessmann's May sale at 62.01 didn't cap the stock, which ran to 75.73 by late June, so I'll treat him as a minor factor. And the post-gap drift shows the selling wasn't finished. It doesn't tell us how much was left to price. On execution, you're right that only two closes in nine sessions got above 55.5. Patient limits should run from the 10 EMA near 55.4 up to the Bollinger middle near 56.1, not out to 56.4. I take your three-piece schedule: about 40% of the reduction now at 55.2 to 55.5, about 30% on limits to 56.1, and the rest at market by October 16 or a week before the confirmed print, whichever comes first.

Now the two places I'm holding.

First, the residual. Conservative, your 11% exposure number double-counts, as the neutral said. The 14% gap already includes day-two follow-through, and the 22% drift unfolded over seven weeks, which is what the stop is for. At half size the event loss is about 7 points of the original position, and at 0.35x it's about 5. That's a two-point difference, and the upside has the same shape. You say a good print runs into the 59 to 61 wall, but a gap is a gap. A reverse move of the same 14% from 55.22 lands near 63, through the 200 SMA at 61.32. That isn't my base case, since the cut rules are a coin flip with a bearish tilt. But with the dollar swing about symmetric, going from 0.5x to 0.35x gives up real participation to shave variance we've already cut by half. So I'd aim for the neutral's 0.4 to 0.5x, going to the low end if CARR is already an oversized weight and staying at half if it's an ordinary position.

Second, hedging stays optional, and the ceiling stays at half without one. Sizing is the control that needs no options access, and we've already used it.

On buybacks, you're right that the Q3'25 mismatch of $224M of free cash flow against $785M of buybacks is a real reason to trim. It's already built into the plan. It argues for being out of full size, not for a specific residual.

The amended plan is this. Check the earnings date today. Work the reduction in the three pieces above, with the 59.3 to 59.8 order as a bonus only. If the stock closes above 56.4 with OBV making a higher low and RSI over 50, sell into that strength anyway, because the risk is the print, not the chart. Use a resting stop at 52.3 to 52.4, or a daily close below 52.65 if the caller can't place one. Don't add anywhere in this range. Scale everything to the caller's actual position, and trim less if they're already underweight.

This is still the bold call. It cuts the exposure that has nothing in its favor, which is full size into a binary print on a levered story with negative OBV. It also keeps real exposure to the one outcome that could pay, a clean Q3 and a reverse gap.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: We're close enough now that I'll mostly say yes and then defend two things.

Conservative, you're right about the first piece. A limit at 55.5 sits above the 10-01 high of 55.24, so it depends on a rally that eight sessions of tape haven't delivered. Make the first 40% marketable around 55.2. Patience is worth paying for in the middle 30%, on limits from the 10 EMA near 55.4 up to the Bollinger middle near 56.1, because that range has actually traded.

You're also right about the stop. A resting order at 52.3 does nothing if a bad print opens near 47.5. Size and the exit rule carry the weight inside the event window, and the stop only covers the drift path.

I'll take the pre-committed exit with the neutral's two refinements: a guidance cut counts as a trigger, and if a cut rule trips while the stock is up, we reassess the same day instead of selling blind. I don't want "no wait-and-see" applied mechanically. The gross margin rule needs only about 100 bp of compression, so it could trip on a day the market likes the orders and the guidance. Selling into strength on a rule alone would throw away the optionality the residual exists to keep. If the rule trips and the stock gaps down, I agree the residual goes the next session. That's ugly tape, but it beats improvising.

I also need to correct myself. I kept saying "half of whatever the caller holds," and the trader's plan says about 0.5x standard allocation. That's the same thing for someone at standard weight, but an overweight holder trims more and an underweight holder trims little or nothing. I'll also use the neutral's implied-move idea. If the options market prices a move well under 14%, there's more room toward half. If it prices well over, stay at 0.4x or lower.

On the residual, I'll give you the default. With no portfolio context, 0.4x is a fine starting point, and I'd rather concede three points of variance than argue over the second decimal. Your 11-versus-8 tail comparison is arithmetically fair. But it assumes a holder frozen through a seven-week second leg, and your own exit rule is built to cut that leg short. The tail also isn't the base case, and the upside has the same shape, so the gap between 0.4x and 0.5x is a point or two of the original position either way.

Here is where I hold. First, no hedge requirement. Using a collar or put spread as a license for 0.5x is circular, as the neutral said. A collar caps the upside that justified the residual, and a put spread bought into an earnings window means paying up to hold something we could simply not hold. The ceiling is half, hedged or not.

Second, the residual has to be a real position. Q2 was not a disaster. Revenue grew 3.9%, free cash flow was $810M, and there's $815M of assets held for sale that could point to deleveraging. A clean Q3 with intact margins and guidance can still surprise a stock that has confirmed nothing bullish and sits 27% off its peak.

The part of this I like most is that trimming isn't only defense. Selling about 60% of the position now buys us the right to be aggressive after the print, with information. If the cut rules hold and guidance is intact, we have dry powder to rebuy on a confirmed setup: a close above 56.4, OBV making a higher low, and RSI above 50. If they break, we've avoided most of the damage. Holding full size gets neither outcome. That is the bold version of this trade.

So the plan is this. Look up the earnings date today and set the backstop at the earlier of October 16 or a week before the confirmed print. Sell 40% of the reduction now, marketable near 55.2, and 30% on limits from 55.4 to 56.1. Finish at market by the backstop, or sell into strength sooner if the stock closes above 56.4 with OBV and RSI confirming. Keep a bonus order at 59.3 to 59.8. Aim for a residual of about 0.4x standard allocation with a ceiling of 0.5x. Hold a resting stop near 52.3 to 52.4, or a daily close below 52.65 if that isn't possible. Exit the residual if the print trips a cut rule or guidance is cut and the stock is down. Don't add anywhere in this range.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: I'll mostly agree with you both, then say why I think the plan is still the aggressive call.

Neutral, the stale price is a good catch. Everything we've quoted is the 10-01 close, and orders should be anchored to the live quote. I'd handle the two gap cases differently, though. If CARR opens above 56.4 on its own, nobody needs to pause. That's the sell-into-strength condition we already wrote down, and it's the best fill we'd get. If it opens below 54, I'd still send the first piece. The stop at 52.3 would then be only about 3% away, and a stock walking toward its stop is when you want less size. A quick re-check is fine, but the thesis hasn't changed overnight.

Your 24/18/18 translation is right. At standard weight, going to 0.4x means selling about 60% of the position, and 40/30/30 of that is the split you gave. Conservative, your tightening is also right. Someone at twice standard weight sells 80% of what they hold. Someone underweight sells little or nothing and just follows the exit rules. I also like your point that proceeds shouldn't rotate into another rate-sensitive cyclical. Selling CARR to buy a lookalike swaps one housing-and-construction bet for another and takes on the same macro risk we can't see. I'd rather sit in cash and wait for a real setup.

I concede two points to Conservative. You're right that "reassess" is how people talk themselves into holding. If a cut rule trips and the stock is up, the residual gets cut by at least half that day. Guidance decides the rest. Neutral's caveat about the $495M line being exactly Q3'25's operating income is why guidance has to be the tiebreaker. You're also right on the rebuy. The 56.4, OBV and RSI trigger is the same one we're selling into before the print. After the print it only means something if the cut rules held and guidance is intact. Neutral's post-print test, holding the gap-day low or reclaiming the 50 SMA, is better than my old levels. Rebuy in stages and never above standard allocation.

Neutral, I accept your correction too. Holding full size does get the full upside of a clean print. What the 60% reduction buys is a better-informed decision, and the price is the first leg of a gap-up. That is a trade. I think it's a good trade because we'd be giving up a coin-flip gain to avoid a gap we've seen this stock deliver. But it is a trade and should be described that way.

On the 0.4x versus 0.5x question, I'll stop defending the second decimal. At a 14% gap it's about 5.6 points versus 7 of the original position. The trader's anchor is 0.5x of standard allocation, and 0.4x as the default with 0.5x as the ceiling is a reasonable tilt toward caution. The options-implied move is the tiebreaker, since it costs nothing to look at. If it's near or above 14%, go to 0.4x or lower. If it's well under, half is fine. Concentration breaks any remaining tie.

Here is why I still think this is the bold version. The cautious move is to hold and wait, or to buy because it looks cheap. This plan does neither. It takes a stock with every trend tier down, negative OBV, margins compressing, short-term debt up from $468M to $1.64B and a binary print ahead, and cuts about 60% of it at prices we can mostly get now. The freed capital then waits for the one moment we'd actually want to act, after the print, when we know whether the cut rules held and what guidance says. A clean quarter with intact guidance should be bought. A broken one will have cost us about 40% of the damage. That's a better position than full size going into the print. It also beats a full exit, because the residual still captures a surprise.

For the index card, with its own backstop: check the live quote and the earnings date today. The backstop is the earlier of October 16 or a week before the confirmed print. Sell 40% of the reduction now at marketable prices near the live quote, and put 30% on limits from about 55.4 to 56.1. Anything unfilled turns into a market order at the backstop. If the stock closes above 56.4 with OBV making a higher low and RSI above 50, sell into that sooner. Keep 59.3 to 59.8 as a bonus order only. The residual is 0.4x standard allocation with a 0.5x ceiling, lower if the implied move is large or the position is oversized. Use a resting stop near 52.3 to 52.4, or a daily close below 52.65 if that isn't possible, knowing it only covers drift and not a gap. If the print trips a cut rule or guidance is cut and the stock is down, the residual goes the next session. If a rule trips and the stock is up, cut at least half that day, and the rest goes unless guidance is clearly intact. Don't add anywhere in this range. Rebuy only after the print, in stages, with fundamentals and a post-print technical setup both confirming. Hedging is optional. Taxes and lot selection can change the sequencing but not the direction or the deadline.

FINAL TRANSACTION PROPOSAL: SELL

Conservative Analyst¶

Conservative Analyst: I'll start with where I agree. Trimming is the right direction. Where I disagree is that the plan, as written, is less conservative than it sounds, because most of its risk reduction depends on things we don't control.

Start with the entry. The first tranche at 56.5 is plausible, since the recent closing range tops out at 56.37. But the second tranche at 59.3 to 59.8 needs about a 7 to 8 percent rally in a stock with a death cross, three down SuperTrend tiers and OBV at a lower low. The aggressive analyst says the plan doesn't need a bounce. In that case the real plan is "sell at market a week before earnings," and that date is unconfirmed. So the trigger for the fallback is a date we don't have. If the reason to cut is gap risk, cut on a calendar deadline we can actually set, like mid-October, and don't wait for a rally that the volume data says is unlikely.

Second, the stop. A daily close below 52.65 doesn't protect against the event the plan is built around. The aggressive analyst's own gap assumption is 14 percent. From 55.22 that lands near 47.5, well through the stop, and you exit the next session at whatever the market gives. The residual half position keeps the full gap exposure. It's also worth noticing that the 14 percent comes from one observation, the late July drop. The stock then kept sliding to 53.88 by mid-September, about 22 percent below the pre-gap close. One sample isn't a ceiling on the downside. If someone wants to keep a residual into the print, I'd rather see it hedged with defined-risk protection, if they can trade options, or sized below 0.5x. A hard stop order is better than a close-based one, even if it whipsaws sometimes.

Third, the CEO purchase. I'd push back on using it as a floor. He bought about 19,300 shares for roughly $1M in November 2025. His January award was nearly 91,000 shares, almost five times larger. The purchase is also eleven months old and predates the weak Q4 and Q1 results and the Q2 margin compression. And the 52.65 stop coincides with the lower Bollinger band, so that overlap with his cost basis is a coincidence. It isn't support.

On held-for-sale assets, $815M is a carrying value, not proceeds, and it's under 8 percent of the $10.6B net debt. Even a clean sale barely moves leverage, and it takes away some EBITDA. I wouldn't lean on that to justify keeping half the position.

The balance sheet is what worries me most, and Q3 is the quarter where it bites. Last Q3, free cash flow was $224M, buybacks were $785M, and commercial paper filled the gap with $444M. Short-term debt is now $1.64B against $1.34B of cash, working capital is $183M, and shareholder returns already ran about $0.86B ahead of free cash flow over the year. If management repeats last Q3's pattern, short-term borrowing climbs again right as the stock is weak. Add tangible book of negative $7.9B and 56 percent of assets in goodwill and intangibles, and continued margin pressure raises questions beyond one quarter's EPS.

On the cut rules, I'd say the aggressive analyst's arithmetic is rough but the conclusion holds. The $495M threshold is exactly Q3'25's operating income, so the rule amounts to "no year-over-year decline." Q2 operating income fell 3.1 percent. Repeat that and you get about $480M, below the line. His margin-based version gives about $465M. Both are crude extrapolations in a seasonal business, but the bar is razor thin.

On sentiment, I agree with leaving the thin StockTwits data out of the thesis. But a reported $1.6M of puts at the $52 strike expiring 10/30 is unverified and could be a hedge. If it's real, it bracket the likely earnings window and sits just under our stop. I wouldn't build on it, but I wouldn't wave it away either. Macro is also a blind spot: no rate data, hawkish Fed headlines, and a fragile-market warning. We can't assume a tailwind.

I expect the neutral view to be to hold until the print for clarity. The problem is that the print is a binary event on a thin-margin, debt-supported story. Holding full size to see what happens is the one choice here with no cushion.

So I'd keep the Sell but tighten it. Do the bulk of the reduction early, rather than waiting for 59 and change. Set a firm calendar deadline for the rest. Take the residual below 0.5x or hedge it, and use a stop order that works intraday. Don't add anywhere in this range. We give up some upside if Q3 surprises, but that cost is smaller than the loss if it doesn't. Conservative Analyst: We've converged more than the tone suggests: all three of us now say Sell, with no adding and a hard calendar deadline. What's left is how much to keep into the print and how to execute. I think you're both still carrying more residual risk than the evidence supports.

Aggressive, you say a half-size residual keeps upside if Q3 surprises. Look at what that upside is. The stock sits below the 50 and 200 SMAs, with the daily SuperTrend stop, upper Bollinger band and 50 SMA stacked at 59.3 to 59.8, and the 200 SMA at 61.32. A good print probably runs into that wall, which is 7 to 11 percent above 55.22. Your own gap assumption is 14 percent down, and you also pointed out that after the July gap the stock fell another 10 percent, for 22 percent cumulative. Use your own drift argument: if repricing keeps going for weeks after a bad print, half size exposes the caller to about 11 percent of the original position, not 7. That argument supports a smaller residual, not a defense of 0.5x. At roughly a third, the same scenarios cost about 4.7 to 7.3 percent.

I'd also challenge the stop logic. You said an intraday stop at 52.65 would likely have been run on 09-18. The low that day was 52.96, 31 cents above the stop, so it wouldn't have triggered. That evidence supports a resting stop order, say a touch under 52.65 around 52.4, not a close-based one. A close-based stop means deciding after the bell and selling into an open that, on this tape, has already gapped. Neutral, you agreed the stop only handles the drift path. If so, it should work on the drift path, intraday.

On the put flow, you said you were leaving the unverified $1.6M of $52 puts out of the thesis, and then you used it to argue protection isn't cheap. That's the same thin retail post doing work after you disowned it. We have no implied volatility. If hedging is unavailable or uncertain, that's an argument for sizing down, because sizing needs no options access. Neutral, your rule that without a hedge they shouldn't go above half is fine as a ceiling. I'd treat half as the maximum, not the target, and aim for roughly 0.3 to 0.4x going into the print.

On execution, limits at 55.5 to 56.4 sound patient, but the top of that band is above every close since 09-25. The 10-01 low of 54.00 was the lowest low since the capitulation day, so the range is drifting toward its floor. Waiting for a 2 percent better price risks a 4.7 percent drop to the stop, and OBV made a lower low on 09-30, which looks like distribution, not accumulation. I'd split it: sell about a third now, work about a third on limits through 56.4, and finish by a fixed date in mid-October, moving earlier if the earnings date is confirmed sooner. The patient part only helps if it actually fills.

Neutral, I'll concede that a liquidity event isn't the base case. Commercial paper is only $685M and interest cover is about 3.8x. But you called the likely outcome "slower buybacks" as if that were mild. Buybacks were about $2.0B over the last year against $1.93B of free cash flow, a large steady bid under the stock. In Q2, EPS fell 11.8 percent even with diluted shares down 3.4 percent. Hold the share count flat and that's roughly a 15 percent decline (my arithmetic). Take away the buyback and you lose the thing that masks margin compression. In Q3'25, free cash flow was $224M against $785M of buybacks, so the stress point is exactly the quarter ahead.

On valuation, you used the roughly 38x trailing EPS to say the multiple isn't the main risk, so don't go below half. If the print is the main risk, the residual is a pure bet on that print, and I've shown its payoff is skewed against us. On Viessmann, whether it's an overhang or a signal, it's a seller of about $1.05B in 12 months, and we don't know what's left. That's one more reason not to count on a clean rebound.

So my amended Sell is this. Start reducing today, with about a third at market-ish prices and a third on limits through 56.4. Finish by a fixed mid-October date or a week before a confirmed print, whichever comes first. Treat 0.5x as the ceiling and aim for roughly 0.3 to 0.4x. Use a resting stop just under 52.65. Don't add anywhere in this range, and scale any trim to the caller's actual position, since we don't know it. We give up some upside if Q3 surprises, but that's a small price against the 14 to 22 percent downside we've already seen this stock deliver.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Let me start by conceding the things you caught. I was wrong about the closes. 09-25 at 56.37 and 09-28 at 55.87 were both inside the 56.4 band, so I overstated that. Your patient limits from the 10 EMA near 55.4 up to the Bollinger middle near 56.1 are better than mine. You're also right that the buyback only masks about 3 points of the 11.8% EPS decline, and that a resting stop near 52.3 to 52.4 fixes the stop problem. I'm happy with the three-piece schedule and the October 16 backstop. The only things left are the size of the residual and one flaw in how you've both dismissed the drift risk.

You both say my 11% number double-counts because the stop handles the seven-week drift. It doesn't, and the July sequence shows why. The stock went from 69.33 to 59.92 in two sessions, then lost another 10% to 53.88. A gap goes through a resting stop, so the stop only works on a drift path that starts above it. If a bad print takes CARR from 55.22 to about 47.5, the stop at 52.3 is already gone. Any follow-through after that, the same 10% we saw in July, lands on whatever you're still holding, unless someone decides to sell into the gapped, already-damaged tape. On that path, half size loses about 11 points of the original position and 0.35x loses about 8. I'm not calling that the base case. It's the observed path of this exact stock last time.

That leads to a rule I'd add. The cut rules, gross margin under 25.0% or operating income under $495M, can only be read after the print, so they can't protect us from the gap. They can stop us from holding a broken thesis afterward. I'd pre-commit that if either rule trips, the residual goes the next session with no wait-and-see. Otherwise we're back to holding half a position in a thesis that the bull's own rules say has failed.

On the symmetry argument, a 14% reverse gap to about 63 is arithmetically fair. But the downside has been observed twice in this window, in July and in September. The only sharp rally we have is the bounce from 59.92 to 65.69 by 08-04, about 9.6%, and it failed. No bullish signal has confirmed, and we've all called the cut-rule outcome a coin flip with a bearish tilt. A bet that's flat to slightly negative in expectation isn't one to hold more of than we have to. The two-point difference between half and a third is also small for a reason: so is the gain from keeping the extra. If it really is a wash, the person who doesn't know the caller's portfolio should take the lower-variance side.

That's my objection to the neutral's tiebreaker. "If it's an ordinary weight, 0.5x is defensible" puts the burden of proof on the smaller residual, and we know nothing about the caller. The default should be the cautious end, and the caller should justify going higher, not lower. So I'd plan on about 0.4x, treat 0.5x as available only with a collar or put spread, and never go above it.

One more small point on execution. A limit at 55.5 sits above the 10-01 high of 55.24, so the first piece shouldn't depend on a rally. Make that first 40% marketable at about 55.2, and let the patient limits carry the middle 30%.

So we're nearly aligned. The only edits I'd make are a default residual of about 0.4x, a marketable first piece, and a next-session exit if the print breaks the cut rules. I'll also hold the line on no adding anywhere in this range.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: We're now arguing over a point or two of position size, so I'll say where I'm moving and where I'm still holding.

I'll give ground first. Neutral, you're right that making a collar or put spread the price of holding 0.5x is circular. A collar caps the upside that justified keeping the residual, and a put spread bought into an earnings window means paying up to hold something we could just not hold. I'm dropping the hedge condition. Hedging stays optional, size does the work, and 0.5x is the ceiling either way.

You're also right that my 11-versus-8 comparison assumed a holder frozen through the whole second leg, and I shouldn't use that as the base case. Calling the bet flat to slightly negative was my judgment, not a finding. I'll take your implied-move idea too, since it's free. If the options market prices a move at or above that 14%, I'd go to 0.4x or lower. If it prices well under, I'd still stop at 0.5x.

Aggressive, I accept your same-day reassessment if a cut rule trips while the stock is up. But "reassess" is how people talk themselves into holding. Write down now what that reassessment is. If a rule trips and the stock is up, the residual still gets cut at least in half that day into the strength, and the rest goes if guidance isn't clearly intact. If a rule trips and the stock is down, the residual goes the next session, as agreed. Otherwise the rule is only a suggestion, and the whole point was removing discretion from the worst moment.

The rebuy idea has an inconsistency. You want dry powder to rebuy after the print on a close above 56.4, OBV making a higher low, and RSI above 50. That is the same signal we're saying to sell into before the print. The only thing that can change its meaning is the print itself. So a rebuy should need the cut rules holding and guidance intact, plus the technical confirmation, with no technical-only rebuys. A good print will probably gap well above 56.4, so the rebuy will likely be at a higher price. That's the cost of being out of the binary event, and I'm fine paying it.

On Q2 not being a disaster, I agree it wasn't, but the picture is thinner than you make it. Revenue grew 3.9%, yet operating income fell 3.1%, EBITDA fell 6.7%, and EPS fell 11.8% even with 3.4% fewer shares. The $810M of FCF was a seasonal Q2 number, and Q3 last year was $224M against $785M of buybacks. The $815M held for sale is a carrying value, under 8% of the $10.6B net debt, and a sale takes EBITDA out with it. It supports not exiting entirely, but it doesn't justify more than the 0.4x default.

On the default, you accepted 0.4x, Aggressive, and you want to defend the second decimal on 0.5x. The tiebreaker should be concentration, as Neutral said. Neutral, I'd tighten your clarification. If the caller is overweight, 0.4x applies to standard allocation, not to their current holding. Someone at twice standard weight sells down to 0.4x standard, which is 80% of what they hold. If they're already underweight, they trim little or nothing and just follow the exit rules. We know nothing about the portfolio, so the cautious end is the default and the caller can argue upward from there.

One execution note. The first 40% should be genuinely marketable around 55.2, and the patient 30% should have a deadline attached. If the limits between 55.4 and 56.1 haven't filled by the October 16 backstop or the earlier pre-print date, they convert to market. That deadline matters more than any price level.

So here's where we land. Look up the earnings date today. Sell about 40% of the reduction now at market-ish prices near 55.2, and place about 30% on limits from 55.4 to 56.1. Finish at market by October 16 or a week before the confirmed print, whichever is first, and sell into strength sooner if the stock closes above 56.4 with OBV and RSI confirming. Keep the 59.3 to 59.8 order as a bonus only. Aim for a residual of 0.4x standard allocation with a hard ceiling of 0.5x, and go lower if the implied move is large or the position is oversized. Use a resting stop near 52.3 to 52.4, or a daily close below 52.65 if the caller can't place one. Sell the residual the next session if a cut rule trips or guidance is cut and the stock is down. If the stock is up, cut at least half that day. Don't add anywhere in this range, and rebuy only after the print with fundamentals and technicals both confirming.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: We're down to a few small items, so I'll be brief on what I accept and then spend time on the places where the plan still leans optimistic.

Neutral, the stale quote point is right, and I agree the plan should fit on an index card. I accept your 24/18/18 translation and your point that the proceeds should sit in cash, not rotate into another housing-and-construction cyclical. Aggressive, I appreciate you taking the written same-day rule and the rebuy conditions. You're also right that holding full size keeps the full upside of a clean print. I never argued otherwise. I'd just say the two sides aren't symmetric for a firm that protects assets. Missing the first leg of a gap-up costs us opportunity. Sitting through a gap-down on a levered, buyback-dependent story costs us a realized loss.

First, the open-below-54 case. Aggressive, you said you'd still send the first piece, and you added that a stock walking toward its stop is when you want less size. Follow that through. If the stock opens below 54, the patient limits at 55.4 to 56.1 sit 3 to 4 percent above the market and won't fill. The middle 30% only works when the stock is strong, so it does the least when the stock is weak. I'd convert it to market on a weak open instead of leaving it resting. It's also worth being honest about the numbers. You said the plan cuts about 60% at prices we can mostly get now. Only the first 40% of the reduction is marketable, which is about 24% of a standard-weight position. Until the limits fill, the caller is still holding roughly 0.76x, not 0.4x.

Second, the stop. As written, it protects the residual. During the ten sessions before the backstop, the unsold shares are exposed too. The resting stop near 52.3 to 52.4 should be live from today on everything the caller still holds, not just the final residual. If it trips mid-window, the whole position is out, and the rebuy rules apply from there.

Third, the implied move. You've both let it push the residual up to 0.5x if it's well under 14%. I'd use it in one direction only. The implied move is the market's average expectation, not the tail. Our 14% figure is one observation of a two-day gap, followed by weeks of drift. A stock priced for a 7% move can still gap 14%, and that is what a tail is. If the implied move is near or above 14%, go below 0.4x. If it's lower, that is not a reason to go above 0.4x. Half is for a caller with concentration headroom and a reason of their own to want more participation. A low implied move alone doesn't supply one.

On the October 16 date, Neutral, the idea that Carrier reported in late October last year is from memory, not from our tools. It's a reasonable guess, but the backstop is the earlier of October 16 or a week before the confirmed print, so it holds either way. I'd also remember that ten sessions is a long window in a market the Fed headlines and Gundlach's comments call fragile, with OBV still making lower lows. That's one more reason the stop and the weak-open conversion matter. Taxes and lot selection can change the order of sales, but they shouldn't move the deadline. Tax lots are the classic reason people end up holding into a binary event.

So my version is the shared plan with three edits. Convert the patient piece to market on a weak open, run the stop on everything still held, and use the implied move only to go lower, not higher. My default is 0.4x standard allocation, with 0.5x as a ceiling that needs a concentration reason and not a low implied move. The rest stays as agreed: the earlier of October 16 or a week before the print as the backstop, selling into strength sooner if the stock closes above 56.4 with OBV and RSI confirming, and the next-session or at-least-half-that-day exit rule if the print trips a cut rule. We don't add anywhere in this range, and we rebuy only after the print, in stages, with fundamentals and a post-print technical setup both confirming.

FINAL TRANSACTION PROPOSAL: SELL

Neutral Analyst¶

Neutral Analyst: I think you two agree more than your tone suggests. Neither wants full size into the print, and both accept a sized cut. The disagreement is about execution, and each of you has a real hole.

Aggressive, the conservative is right that the plan is less self-sufficient than you claim. The first tranche at 56.5 is reasonable. The second needs a 7 to 8 percent rally, and the stock hasn't closed above 56.37 since the 09-18 low. A deadline of "a week before the print" hangs on an earnings date nobody has confirmed. A cut motivated by gap risk should be tied to a date we control.

The CEO's $52.62 purchase also isn't a floor. It's eleven months old and predates the weak Q4 and Q1 and the Q2 compression. The stop sits there because the lower Bollinger band does.

Your cut-rule arithmetic is directionally fair, but the error bars are wide. The gross margin trigger needs only 100 bp of year-over-year compression, and Q2 showed 170. Operating income has to fall less than about 35 bp in margin on 3.9% revenue growth to hold $495M. That's a coin flip with a bearish tilt, not a forecast of failure. The market also already punished Q2 hard for a 3.1% operating income decline, so some of that risk is priced in. We can't say how much.

I'd also weight the Viessmann selling less than you do. He's unwinding a stake from a deal, and that's a supply overhang, not an operating signal.

Conservative, I think you overreach in a few places. Dumping the bulk at 55.22 sells the middle of a range, below the 10 EMA, right after capitulation volume and an RSI bounce from 27. That said, the gap between 55.22 and 56.5 is only about 2 percent. So I'd start working the first tranche now with limits in the 55.5 to 56.4 band, which is inside the recent closing range and should fill without chasing.

Your options suggestion assumes access, and we have no implied volatility data. Protection bought into an earnings window, with $1.6M of reported put activity nearby, is probably not cheap. I'd call it optional, not a requirement.

On the stop, you're right that a 14 percent gap blows through 52.65, but that means the stop type is secondary. Size is what controls gap risk. The stop only handles the drift path. A hard stop at 52.65 would have survived the 09-18 capitulation low of 52.96 by only 31 cents, so I'd keep it close-based outside the event window.

The balance sheet matters, but "Q3 is where it bites" is too strong. Of the $1.64B in current debt, only $685M is commercial paper. FCF covers the dividend about 2.5 times, and interest cover is about 3.8x. Buybacks are discretionary, so the likelier consequence is slower buybacks, which removes a support for the stock. That's a reason to size down, not to expect a liquidity problem.

One thing neither of you said: using the aggressive's own 825M shares, market cap is about $45.5B. That's roughly 38 times trailing EPS and high-teens EV to EBITDA. These are my arithmetic, since the valuation profile was withheld, and trailing numbers are depressed by the trough quarters. Still, "down 27 percent" is not a margin of safety. That supports trimming, but it doesn't argue for going below half, because the main risk is the print, not the multiple.

So I'd keep the Sell but change how it executes. Look up the earnings date today. Aim for roughly half the current position. Place about half of the planned reduction as limits between 55.5 and 56.4, starting now. Complete the rest by a hard backstop, the earlier of mid-October or a week before the confirmed print. Keep a resting limit at 59.3 to 59.8 for the remainder as a bonus, not a requirement.

If the stock confirms with a close above 56.4, OBV making a higher low and RSI above 50, sell into that strength. The deadline stays regardless, because the gap risk comes from the print, not the chart. Exit the residual on a daily close below 52.65 and don't add anywhere in this range. If the caller can cheaply collar or buy a put spread on the residual, they can hold a bit more than half. Without a hedge, they shouldn't go above it.

Since we don't know the portfolio, "half" means half of whatever they hold now. If the position is already underweight, the trim should be smaller. Neutral Analyst: I'll take you both in turn, because the remaining gap is smaller than the tone suggests. We all say Sell, no adding, a calendar deadline, and size as the main control. What's left is roughly 0.35x versus 0.5x, the stop type, and how patient to be on the first fills.

Aggressive, a few of your claims don't hold up. You said an intraday stop at 52.65 would likely have been run on 09-18. The low that day was 52.96, so it wouldn't have been. My earlier point was that 31 cents is thin margin, about 0.2 ATR, not that it would have triggered. The conservative is right that the evidence supports a resting stop, just placed lower, around 52.3 to 52.4, under both the band and the swing low. I'll concede that.

You also said the post-gap drift to 53.88 proves Q2 wasn't priced in. Drift after a gap has many causes, including tape, flows and a fragile market. It tells us the selling wasn't done, not what's left to price.

On Viessmann, the stock ran from his 62.01 sale on 05-20 to 75.73 by 06-25, so that overhang didn't cap the price. I'd keep it as a minor factor.

Finally, you called valuation your strongest support and then said not to lean on it, because trailing EPS is distorted by trough quarters and a noisy tax line. It can't be both. It's a reason not to call the stock cheap, nothing more.

Conservative, your residual-risk math has a double-count. You applied the 22 percent cumulative move to the half position and got 11 percent. But that 22 percent unfolded over about seven weeks, and the stop exists to handle exactly that kind of drift. The event risk is the gap, and the 14 percent two-day move already includes the day-two follow-through. So at 0.5x the event loss is about 7 percent, and at roughly 0.35x it's about 5. That's about two points of the original position.

The upside side of the ledger is similar. A move into 59 to 61 is 7 to 11 percent, which is 3.5 to 5.5 points at half size versus 2.5 to 4 at 0.35x. That's also about a point or two. Resistance is a place to reassess, not a hard ceiling, since a good print can gap through it. So the choice between half and a third is closer to a wash than your framing implies.

On execution, you said the top of the 56.4 band is above every close since 09-25. That's not quite right. 09-25 closed at 56.37 and 09-28 at 55.87, both inside the band. What is true is that the last three closes were 55.38, 54.86 and 55.22, and the 10-01 high of 55.24 never reached 55.5. So the patient limits should start lower, from about 55.4 (the 10 EMA) up to around 56.1 (the Bollinger middle), not all the way to 56.4.

On buybacks, you said that without the share-count reduction Q2 EPS would be down about 15 percent. That's right, but the buyback only masks about 3 points of an 11.8 percent decline. The rest comes from tax rate, minority interest and operating compression. I'll grant your Q3 point, though. Last year's Q3 had $224M of free cash flow against $785M of buybacks, and that mismatch is a real reason to trim. It argues for trimming, not for a particular residual.

On the put flow, you called out the aggressive for using a post he'd disowned, but that line was mine first. You're right that we have no implied volatility. Hedging should be optional because we don't know the caller's access or prices, not because of one retail post.

So here is my adjusted plan. First, look up the earnings date today. Set the deadline at the earlier of October 16 or a week before the confirmed print.

Second, execute in three pieces. Work about 40 percent of the reduction now with limits at or just above the market, around 55.2 to 55.5, so the conservative's urgency is respected. Put about 30 percent on limits from roughly 55.5 to 56.1. Finish the rest by the deadline at market. Keep a resting order at 59.3 to 59.8 only as a bonus. If the stock closes above 56.4 with OBV making a higher low and RSI above 50, sell into that strength anyway.

Third, for sizing, aim for a residual of about 0.4 to 0.5x of what the caller holds, never above half. Since we don't know the portfolio, the tiebreaker is concentration. If CARR is already a larger weight than a normal single name, go to the low end. If it's an ordinary weight and the caller wants some participation in a surprise, 0.5x is defensible. If the position is already underweight, trim less.

Fourth, for the stop, use a resting order near 52.3 to 52.4 if the caller can place one. Otherwise use the daily close below 52.65. Inside the print window, neither the stop nor the stop type protects against a gap, so size and the deadline carry the weight.

Fifth, no adding anywhere in this range, and options protection is a nice extra, not a requirement.

This keeps the aggressive's patience on price for part of the fills and the conservative's firm deadline, intraday stop and smaller ceiling. It avoids holding full size into a binary print on a thin-margin, short-term-debt-funded story, and it avoids dumping the whole position in the middle of a range right after capitulation volume.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We're down to three small things: how big the residual is, whether the print triggers an automatic exit, and how the first piece gets filled. I'll take them in turn.

Conservative, you're right on the first piece. A limit at 55.5 sits above the 10-01 high of 55.24, so it's a hope, not an order. I'll take a marketable first 40% around 55.2 and keep the patient middle 30% between the 10 EMA near 55.4 and the Bollinger middle near 56.1. The October 16 backstop stays, or a week before the confirmed print if that's earlier.

I also like your pre-committed exit, because it fixes a real hole. The cut rules can only be read after the print, and without a rule the residual becomes a wait-and-see holding in a thesis the bull said had failed. I'd widen the trigger to include a guidance cut, since the rules are only a Q3 snapshot and we have no guidance data. I'd also be honest about the cost. If the print gaps CARR toward 47.5 and you sell the next session, you sell into the worst tape. That's still better than improvising under stress, but it isn't free. The bar is also only about 100 bp of year-over-year gross margin compression, so the rule could trip while the stock rallies. In that case I'd want a same-day reassessment, not a blind sale into strength. If the rule trips and the stock is down, the residual goes the next session.

On the residual, I think each of you is stretching a little. Conservative, the 11-versus-8 comparison assumes the full July path repeats: a 14% gap, then another 10% over weeks, with the holder frozen throughout. That path happened once, and in July the second leg took seven weeks. Your exit rule exists to cut that second leg short, and you can't use it to answer my double-counting point and also count the full follow-through as unprotected. Calling the bet flat to slightly negative in expectation is also an assertion. We called the cut-rule outcome a coin flip with a bearish tilt, and that's all the data supports.

Aggressive, the symmetry argument is generous. A 14% reverse gap to 63 is arithmetically fair, but the only sharp rally we've seen was the 9.6% bounce to 65.69, and it failed. A clean print more plausibly runs into the 59 to 61 cluster, which is 7 to 11 percent. At 0.4x that's about 3 to 4.5 points of the original position, versus 3.5 to 5.5 at half size. That's too small a difference to defend the larger residual.

On hedging, I'd push back on something you both did. Conservative, you'd allow 0.5x only with a collar or put spread. But a collar caps the upside that justified keeping the residual, and a put spread bought into an earnings window means paying up to hold something you could simply not hold. Using a hedge as a license to hold more is circular. Aggressive, calling hedging optional is right, but that's no reason to default to the top of the range. So my answer is 0.4x as the default and 0.5x as the ceiling, with no hedge required. The caller can go up to half if CARR is an ordinary weight and they want participation in a surprise, and they should stay at 0.4x or lower if it's already oversized.

One clarification neither of you made: the trader's plan anchors on 0.5x of standard allocation, not half of current holdings. If the caller is at standard weight, that's the same thing. If they're overweight, the trim is bigger than half. If they're already underweight, it may be little or nothing.

Finally, one cheap piece of information we're all missing is the options-implied earnings move. The 14% gap comes from one observation. If the caller can see the implied move without trading anything, and it's well above 14%, they should lean toward 0.4x or lower. If it's well below, they can lean toward half.

So the plan is this. Look up the earnings date today and set the deadline at the earlier of October 16 or a week before the print. Sell 40% of the reduction now, marketable near 55.2, and 30% on limits from 55.4 to 56.1. Finish at market by the deadline, and sell into strength anyway if the stock closes above 56.4 with OBV making a higher low and RSI over 50. Keep a bonus order at 59.3 to 59.8. Aim for a residual of about 0.4x with a ceiling of 0.5x, hold a resting stop near 52.3 to 52.4 for the drift path, and sell the residual the next session if the print trips a cut rule or guidance is cut and the stock is down. Don't add anywhere in this range.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: Before I give my last view, I'll say where each of you is right and where each is still overreaching, since the remaining gap is small.

Conservative, you're right that "reassess" is how people talk themselves into holding, so I accept your written version. If a cut rule trips and the stock is up, cut at least half the residual that day and let guidance decide the rest. If it trips and the stock is down, the residual goes the next session. One caveat: the $495M operating income line is exactly Q3'25's number, so a $490M print with raised guidance would trip it. That's why guidance has to be the tiebreaker on the second half, as you wrote. I'd also resist adding more rules. A plan that has to be executed on a gap day should fit on an index card. The more branches we add, the more discretion creeps back in.

Your rebuy point is also right. The technical trigger is the same one we're selling into, so it can't count as confirmation by itself. I'd add that after a print the old levels stop mattering. If the stock gaps up, 56.4 is irrelevant, and a sensible rebuy test is something like holding the gap-day low or reclaiming the 50 SMA. Rebuy in stages, and never above standard allocation. Aggressive, I like the dry-powder idea, but "holding full size gets neither outcome" is overstated. Full size gets the upside of a clean print in full. What you're really buying with the 60% reduction is a better-informed decision, at the price of the first leg of a gap-up. That's a fair trade, but we should describe it as a trade.

Aggressive, I'm glad you've given up on the second decimal, and I'd gently note that most of your remaining objections are to conditions we've already dropped. Nobody is requiring a hedge anymore. The remaining disagreement is 0.4x versus 0.5x, and at a 14% gap that's roughly 5.6 points versus 7 of the original position. That doesn't justify another round. Take 0.4x as the default, 0.5x as the ceiling if the options-implied move is well under 14%, and the caller's concentration as the tiebreaker.

Several things haven't been said yet.

First, our reference price is stale. Everything we've quoted is the 10-01 close of 55.22, and today is Friday 10-02. The "marketable near 55.2" piece should be anchored to the live quote. If the stock has gapped meaningfully either way overnight, say below 54 or above 56.4, the schedule needs a quick re-check before anyone sends orders. The same goes for the 52.3 stop, which is only about 2x ATR below where we think the stock is.

Second, the 40/30/30 split is a percentage of the reduction, not of the position. For a caller at standard weight cutting to 0.4x, that means selling about 24% of the position now, 18% on the patient limits, and 18% at the deadline. Someone overweight has a bigger reduction, so the same percentages mean bigger orders. Someone underweight may have nothing to sell, and then only the exit rules apply.

Third, October 16 is two weeks and ten sessions away. If Carrier reports in late October as it did last year, which is unconfirmed, the October 16 backstop will probably be the binding date. That means the patient limits get a real window. If the caller finds an earlier print date, the backstop moves up with it.

Fourth, where the proceeds go matters. If the freed capital goes into another rate-sensitive, construction-exposed cyclical, the caller has swapped single-name risk for the same macro risk. The macro picture is a blind spot, with hawkish Fed headlines and a warning about a fragile market, and we have no rate data. For now the proceeds should sit in cash or in something that doesn't move with housing and commercial construction. I'd rather wait for a confirmed setup in CARR than rotate into a lookalike.

Finally, taxes and costs. We know nothing about the caller's lots or tax position. If the position carries large gains or losses, that could change how to sequence the sales. It shouldn't change the direction or the deadline.

So my plan is as follows. First, check the live quote and look up the earnings date today. Set the backstop at the earlier of October 16 or a week before a confirmed print. Second, sell about 40% of the reduction now at marketable prices, and put about 30% on limits from the 10 EMA near 55.4 up to the Bollinger middle near 56.1. Anything unfilled converts to market at the backstop. If the stock closes above 56.4 with OBV making a higher low and RSI above 50, sell into that strength sooner. Keep 59.3 to 59.8 as a bonus order only. Third, aim for a residual of 0.4x standard allocation, go lower if the implied move is at or above 14% or the position is oversized, and never exceed 0.5x. Fourth, use a resting stop near 52.3 to 52.4, or a daily close below 52.65 if the caller can't place one, and understand that it protects against drift, not a gap. Fifth, run the exit rule as agreed. If the print trips a cut rule or guidance is cut and the stock is down, the residual goes the next session. If a rule trips and the stock is up, cut at least half that day, and the rest goes unless guidance is clearly intact. Sixth, don't add anywhere in this range, rebuy only after the print with fundamentals and a post-print technical setup both confirming, and keep hedging optional.

This sells enough to survive a repeat of July without selling out of a company with real cash generation. It keeps meaningful participation if Q3 surprises, and it takes discretion out of the one day when discretion is most expensive.

FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We're at the point where the remaining disagreement is worth about a point and a half of the original position. At a 14% gap, 0.5x loses 7 points and 0.4x loses 5.6. Most of the value in this plan is the deadline, the written exit rule and the stop covering everything. Let me take Conservative's three edits, then say where Aggressive overclaimed.

First, the weak open. Conservative is right that limits at 55.4 to 56.1 do nothing if the stock opens under 54, and that only about 24% of a standard-weight position is actually marketable on day one. Aggressive's "cuts about 60% at prices we can mostly get now" overstates it. But converting the patient piece to market on a weak open is the opposite mistake. It sells 70% of the reduction into the worst tape of the window, and nothing says the weakness is stock-specific. If it's a fragile-market day, as the Gundlach and hawkish-Fed headlines suggest, CARR often gives some of it back. The fix is to bound the patience by time, not by a stale price. If it opens weak, send the first piece anyway and slide the patient limits to about a percent above the live quote. Give them three sessions, then they go to market. The October deadline doesn't move.

Second, the stop on everything held from today. I agree completely, and it also makes the weak-open conversion less urgent. If the resting stop near 52.3 to 52.4 covers every share, the interim 0.76x is protected on the drift path. A stop about 5% below 55.22 costs roughly 4 points of the original position at 0.76x. That's cheap. The only unprotected risk is the gap, and the backstop is there so the print finds us at 0.4x. If the stop trips mid-window, everything is out, and we don't rebuy until after the print.

Third, the implied move. I disagree with using it in only one direction. Conservative is right that an implied move is an average expectation, not a tail, and that a stock priced for 7% can gap 14%. But our 14% is one realized observation, and the options market is the only forward-looking measure we have. If we'd lower the residual on a high reading but ignore a low one, we're not using the information. We're just leaning on it. Use two keys. A reading near or above 14% takes us to 0.3x to 0.35x. A reading well under that can lift us to 0.5x only if the caller also has concentration headroom and wants the participation. Otherwise it stays 0.4x. That meets Conservative's demand for a reason beyond a low number.

I'd also push back on the "realized loss versus opportunity cost" framing. Dollar for dollar, a gap-up we missed and a gap-down we sat through are the same size. The real asymmetry is the evidence tilt, which is bearish but not strongly so, and that's already why we're selling. Loss aversion isn't a separate argument.

Aggressive, the "bold" label doesn't matter. This is a risk reduction with a free option on a clean print, and it's worth doing for that reason. Your dry-powder point is fair as long as the rebuy waits for the print and requires both the fundamentals and a post-print technical setup.

So here is the card. Check the live quote and the earnings date today. The backstop is the earlier of October 16 or a week before the confirmed print. Sell about 40% of the reduction now at marketable prices. Work about 30% on limits from the 10 EMA near 55.4 up to the Bollinger middle near 56.1, re-anchored to the live quote if the open is weak. Anything unfilled goes to market at the backstop. Sell into strength sooner on a close above 56.4 with OBV making a higher low and RSI above 50. The 59.3 to 59.8 order is a bonus only. The residual is 0.4x standard allocation, lower if the implied move is large or the position is oversized, and 0.5x at most with both keys. A resting stop near 52.3 to 52.4 covers everything still held. If the print trips a cut rule or cuts guidance and the stock is down, the residual goes the next session. If the stock is up, cut at least half that day and let guidance decide the rest. Don't add, don't rotate the proceeds into another housing-exposed cyclical, rebuy only after the print and in stages, and treat hedging as optional.

FINAL TRANSACTION PROPOSAL: SELL

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Cut CARR to about 0.4x standard allocation, with 0.5x as the hard ceiling, before the Q3 print, and make no new purchases. Before trading, check the live quote and the confirmed earnings date. The deadline for finishing the cut is October 16 or one week before the confirmed print, whichever comes first. Sell about 40% of the reduction now at marketable prices. Place about 30% as limits between 55.4 (10 EMA) and 56.1 (Bollinger middle); if the open is weak, move these to about 1% above the live quote and switch them to market after three sessions. Sell the rest at market by the deadline, or earlier into a close above 56.4 confirmed by OBV and RSI. Keep 59.3–59.8 only as a bonus order. Put a resting stop near 52.3–52.4 (or use a daily close below 52.65) on every share held, starting today. Don't average down, hold the proceeds in cash rather than another construction cyclical, and use pre-set rules to decide what to do after the print.

Investment Thesis: The debate supports cutting the position but not exiting it. That makes the rating Underweight (cut exposure), not Sell (exit or avoid). The trader's 'Sell' and all three risk analysts' 'SELL' proposals describe the same thing: a sized reduction to about 0.4–0.5x, not a full exit.

Why reduce: (1) Every trend measure points down. Price is 55.22, below the 50 SMA (59.77, falling) and the 200 SMA (61.32). The 50/200 death cross came on 09-24. SuperTrend is down on the weekly (68.06), monthly (75.98) and daily (59.29) timeframes. OBV made a lower low of -87.22M on 09-30 even though price closed higher than the 09-18 capitulation close, so volume hasn't confirmed the base. The MACD histogram has stalled near +0.25. (2) Margins are already close to the thesis-break levels. Q2'26 gross margin fell 170 bp YoY to 27.2% and operating income fell 3.1% on revenue up 3.9%. If that compression simply repeats on Q3'25's 26.0% gross margin and $495M operating income, gross margin lands near 24.3% and operating income near $465–480M. Both are below the cut rules (gross margin under 25.0%, operating income under $495M). (3) Capital returns are running ahead of cash. TTM shareholder returns of about $2.79B exceeded FCF of about $1.93B by about $0.86B. Current debt rose from $468M to $1.64B, including $685M of commercial paper. Working capital is $183M. Q3 is seasonally where the gap is widest: in Q3'25, FCF was $224M against $785M of buybacks. (4) The stock is not cheap. Using 825M shares, I estimate roughly 38x trailing EPS and about 24x FCF. A 27% fall from 75.73 has not created a margin of safety. (5) The print is a binary event with recent precedent. The July print took the stock from 69.33 to 59.92 (-13.6%) in two sessions, and it then drifted to 53.88 over the next seven weeks.

Why not a full exit: TTM FCF of $1.93B is real, the dividend is covered about 2.5x, net debt/EBITDA is about 3.4x, and interest cover is about 3.8x. $815M of assets are held for sale. The neutral analyst framed the cut-rule outcome as 'a coin flip with a bearish tilt.' A clean print could gap the stock toward 59–63.

On sizing, the conservative analyst's case for a default of 0.4x won. With no portfolio context, the extra point or so of upside from holding 0.5x doesn't justify the extra gap risk (about 5.6 vs 7 points of the original position on a 14% gap). Move to 0.5x only if the options-implied move is well under 14% and the caller also has concentration headroom. If the implied move is 14% or more, go to 0.3–0.35x. Scale to standard allocation: a holder at 2x standard sells about 80% of the position, and a holder already underweight sells little or nothing and just follows the exit rules.

Post-print rules: - If gross margin is below 25.0%, operating income is below $495M, or guidance is cut, and the stock is down: exit the residual the next session. - If a rule trips but the stock is up: cut at least half the residual that day, and let guidance decide the rest. - If gross margin is at least 26.0%, operating income is above $495M, guidance is intact, and buybacks fall back toward the self-funded pace of about $290M a quarter: rebuild in stages, only once the stock holds the gap-day low or reclaims the 50 SMA, and never above standard weight.

These would change the view: a confirmed clean print as above, or a close above 56.4 on rising volume with OBV making a higher low than -87.22M after the print. The view would get more bearish on a close below 52.65 or another commercial-paper-funded quarter of buybacks.

Price target of $53.0: a probability-weighted value through the print. I put 55% on a bear case that repeats the July two-day gap of about 14% from 55.22, giving about 47.5. I put 45% on a relief case into the 59.3–59.8 resistance cluster (daily SuperTrend 59.29, upper Bollinger band 59.63, 50 SMA 59.77), midpoint about 59.55. That gives 0.55×47.5 + 0.45×59.55 ≈ 52.9, rounded to 53.0. That is about 4% below the current price, which fits an Underweight rather than an outright Sell. As a cross-check, 24x TTM FCF works out to about 56 a share, so the stock is fairly priced at best.

Data gaps: there is no confirmed earnings date, guidance, implied volatility, peer multiples or repurchase prices. Those gaps limit confidence and favor less exposure to the event.

Current Price: 55.22

Price Target: 53.0

Confidence: Medium

Time Horizon: 1-3 months